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Abstract

Oligodendrocyte progenitor cells (OPCs) are precursor cells that give rise to
oligodendrocytes. Oligodendrocytes are the cells that form myelin, an arrangement of
membrane sheaths enwrapping axons necessary for the fast transmission of electrical
impulses in the central nervous system (CNS). OPCs generate oligodendrocytes both
during development and adulthood and also after the myelin damage caused by injury or
demyelinating disease.

Generation of oligodendrocytes from OPCs is in part regulated by growth factors. The
major survival factor and mitogen for OPCs is platelet derived growth factor (PDGF).
PDGF and its receptor, PDGF receptor A (PDGFRA), are critical regulators of OPC
proliferation and their differentiation into myelinating oligodendrocytes. PDGFRA gain-offunction can lead to excessive proliferation and is associated with a number of cancers,
including glioma in the CNS. In terms of the role of PDGFRA in OPC differentiation,
there is evidence that suggests that signaling through PDGFRA needs to be inhibited in
order for OPC differentiation to occur.
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The goal of this study is to identify small molecule compounds that inhibit Pdgfra
transcription in oligodendrocyte precursor cells. We hypothesized that inhibition of
Pdgfra transcription by small molecule compounds would result in inhibition of OPC
proliferation and stimulation of their differentiation into mature oligodendrocytes.
Identification of such compounds may provide a novel direction in drug design for
demyelinating disorders or specific types of cancers caused by aberrant Pdgfra
expression.

We identified a group of compounds that downregulated Pdgfra transcription in Oli-neu
cells, a cell line that represents mouse oligodendrocyte precursor cells, and that inhibited
proliferation of PDGFRA-expressing Oli-neu cells and primary mouse OPCs but did not
inhibit proliferation of primary mouse astrocytes and HEK 293 cells, that do not express
PDGFRA, or glioblastoma-derived cell lines. However, these compounds did not
promote differentiation of primary mouse OPCs.
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Introduction

Oligodendrocyte progenitor cells (OPCs, NG2 cells, polydendrocytes) represent a
population of cells in the central nervous system (CNS) that is distinct from all other cell
types (reviewed by Nishiyama, et al, 2009). OPCs are uniformly distributed throughout
the gray and white matter and persist as the largest population of cycling cells in the
adult mammalian CNS (Dawson et al, 2003). They are the major source of
oligodendrocytes (Zhu et al, 2008), cells that generate myelin sheaths necessary for
rapid conduction of electrical impulses in the CNS.

Generation of oligodendrocytes occurs both during development and adulthood in
healthy rodent brain. However, OPCs can give rise to oligodendrocytes in pathological
conditions as well. Upon myelin damage, OPCs proliferate and differentiate to
compensate for myelin loss (reviewed by Miron et al, 2011). In fact, acute myelin lesions
are efficiently repaired (Zawadzka et al, 2010). Chronic lesions however, such as those
found in multiple sclerosis (MS) and its rodent models, are not remyelinated efficiently
(Tripathi et al, 2010). It is not determined why OPCs are unable to repair myelin damage
under these conditions, but one possibility is that OPC are inhibited from differentiation
into myelinating oligodendrocytes (Kuhlman et al, 2008).

OPCs are commonly identified by the expression of platelet derived growth factor
(PDGF) receptor A (PDGFRA). Signaling through PDGFRA is the key mechanism in
regulation of OPC proliferation and differentiation. A large body of evidence indicates
that PDGF is the major mitogen for OPCs (Noble et al, 1988; Richardson et al, 1988;
Barres et al, 1992; Calver et al, 1998; Fruttiger et al, 1999; van Heyningen et al, 2001).
PDGF presence is necessary for OPC proliferation in vitro and its withdrawal causes
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rapid differentiation of OPCs. Studies have suggested the default pathway that OPCs
undertake is differentiation. This pathway is normally inhibited by PDGFRA signaling in
progenitor cells and signaling through PDGFRA needs to be repressed in order for
OPCs to differentiate. Since PDGFRA is present in OPCs, but gets downregulated as
OPCs differentiate, it is likely that PDGFRA and its downregulation are critical factors
that control oligodendrocyte differentiation and that PDGFRA has to be downregulated in
order for OPCs to differentiate (McKinnon et al, 2005; Zhu et al, 2014). However,
molecular mechanisms that lead to PDGFRA repression and therefore trigger
differentiation remain to be defined.

The goal of this study is to identify small molecule compounds that downregulate
PDGFRA transcription. This may contribute in understanding the mechanism of
PDGFRA expression and provide a novel direction in drug design for demyelinating
disorders or specific types of cancers caused by aberrant PDGFRA expression.

To address this goal, we performed experiments outlined in the Specific Aims below.

Aim 1: Identify lead compounds that downregulate the transcription of PDGFRA.
Aim 2: Examine structure activity relationship.
Aim 3: Determine whether the compounds promote OPC differentiation.
Aim 4: Determine whether the compounds inhibit OPC proliferation.

2	
  

Chapter 1 - Background 	
  

Brief history of glia

Early in the 19th century, Theodor Schwann recognized a cell as the fundamental unit of
all living organisms. It was not until well into the 20th century, however, that
neuroscientists agreed that nervous tissue, like all other organs, is made up of these
fundamental units. The major reason was that the first generation of neurobiologists in
the 19th century had difficulty resolving the unitary nature of nerve cells with the
microscopes and cell staining techniques that were then available. As a result, some
biologists of that era concluded that each nerve cell was connected to its neighbors
forming a continuous network, or reticulum. The “reticular theory”	
   of nerve cell
communication, led by Italian neuropathologist Camillo Golgi, was eventually replaced
with	
   “neuron doctrine”	
   by Spanish neuroanatomist Santiago Ramon y Cajal and British
physiologist Charles Sherrington. The histological studies of Cajal, Golgi and many
successors led to the further consensus that the cells of the nervous system can be
divided into two broad categories: neurons and glia.

For the past 160 years, cells in the nervous system have been divided into neurons and
glia (reviewed by Kettenmann and Verkhratsky, 2008). An idea on the brain connective
tissue, the “nervenkitt”, nerve cement or neuroglia was proposed by Rudolf Virchow in
the mid 19th century. The term neuroglia and the concept behind them spread around
the world. Soon after, many different forms of glial cells were described by Deiters,
Henle, Retzius, Golgi and others (Deiters, 1865; Henle and Merkel, 1869; Retzius, 1894;
Golgi, 1903). In the late 19th century, Michael von Lenhossek proposed the term
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“astrocyte” (von Lenhossek, 1893) and slightly later, Kolliker (Kolliker, 1889) and
Anderiezen (Andriezen, 1893) divided those into fibrous and protoplasmic astoryctes.
Pio del Rio-Hortega recognized oligodendrocytes and microglia in the early 20th century
and added them to the growing list of glial subtypes (del Rio-Hortega, 1919; 1921;
1932). It was not until mid 20th century that myelin, the term also introduced by Virchow,
was recognized to be part of the Schwann cell (Geren, 1954).

OPCs as the fourth population of glia

The initial division of glia into three types, astrocytes, oligodendrocytes and microglia,
accomplished in the mid 19th century, has recently been challenged. An entirely new
class of glial cells, oligodendrocyte progenitor cells (OPCs), also known as
polydendrocytes (Nishiyama et al, 2007), has been characterized and proposed as the
4th major population of glia (Nishiyama et al, 2009).

OPCs were discovered in the late 20th century and were thought to be precursor cells
that most commonly generate oligodendrocytes, but can also generate astrocytes in
some cases (Raff et al, 1989; Zhu et al, 2008; Zhu et al, 2011) and even neurons
(Kondo and Raff, 2000; Rivers et al, 2008; Guo et al, 2009; Guo et al, 2010). However,
OPCs are not solely progenitor cells. They can be considered a distinct type of glia for
several reasons. First, they are uniformly distributed population of cells in gray and white
matter of healthy adult rodent brain that persists into adulthood as the major pool of
cycling cells and is as abundant as other cell types (Dawson et al, 2003). Second, the
pattern of expressed markers distinguishes these cells from all the others. In addition,
these is increasing evidence that suggests a population of OPCs persists in adult brain
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and does not differentiate into oligodendrocytes, so it is likely that OPCs have a far more
complex role in nervous system physiology that we are not yet aware of.

OPC developm ent and fate choices

OPCs originate from discrete parts of the ventricular zone (VZ) but the region of VZ that
will give rise to OPCs is different at different time points during development and
temporarily progresses from the ventral towards the dorsal part of the VZ (Warf et al,
1991; Kessaris et al, 2006; reviewed by Richardson et al, 2006). Once committed to
oligodendrocyte lineage, OPCs migrate away from the VZ through the developing CNS
and into what will become the white matter of the CNS (Reynolds et al, 1988; Levine et
al, 1988). OPCs continue to divide after they leave the VZ. Once they settle at their final
destinations, OPCs will exit the cell cycle, express myelin genes and mature to fully
differentiated oligodendrocytes (reviewed by Baumann and Pharm-Dinh, 2001).
However, not all OPCs will differentiate. A population of OPCs persists in the rodent
cortex throughout adulthood (Reynolds et al, 1997; Dawson et al, 2003).

When originally discovered, OPCs were considered bipotent glial precursors and were
named O-2A progenitor cells because in vitro, they were capable of generating both
oligodendrocytes and type-2 astrocytes (Raff et al, 1983). When cultured with PDGF
producing type-1 astrocytes (Richardson et al, 1988) or simply PDGF (Noble et al,
1988), OPCs divide and exhibit features of progenitor cells over a period of several
weeks (Noble and Murray, 1984; Raff et al, 1985; Dubois-Daicq, 1987), perhaps even
indefinitely (Barres et al, 1994). If type-1 astrocytes are removed (Abney et al, 1981; Raff
et al, 1985; Dubois-Dalcq et al, 1986) or PDGF is withdrawn (Noble and Murray, 1984;
Temple and Raff, 1985; Behar et al, 1988), OPCs rapidly differentiate into
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oligodendrocytes. OPCs also differentiate into oligodendrocytes if thyroid hormone has
been added to the culture medium (Barres et al, 1994). To the contrary, addition of fetal
bovine serum (FBS) triggers OPCs to obtain features of type-2 astrocytes (Raff et al,
1983; Raff et al, 1989). Some reports suggested that, depending on culture conditions,
OPCs could differentiate into neurons as well (Kondo and Raff, 2000).

OPC fate choice in vivo has been controversial until the generation of transgenic mice
that express cre recombinase under the control of OPC-specific genes. With this
approach, it has been confirmed that that these cells are precursor cells that most
commonly generate oligodendrocytes. However, their multipotency is limited in vivo. It
was indeed true that OPCs can generate astrocytes in healthy rodent tissue as well, but
this fate choice occurs only during prenatal development and only in specific regions of
the forebrain (Zhu et al, 2008; Zhu et al, 2011). Although few studies showed that OPCs
generate a small number of neurons in vivo (Rivers et al, 2008; Guo et al, 2009; Guo et
al, 2010), the question of their neuronal fate is still debatable.

Markers that identify stages of OPC developm ent

Starting from neural stem cell up to fully differentiated myelinating oligodendrocyte,
oligodendrocyte lineage cell goes through several stages. Each stage can be identified
by the expression of specific antigenic markers. Although these markers are commonly
used to identify different stages of oligodendrocyte development by immunocyto- and
histochemistry, it needs to be kept in mind that they are not solely markers, but also
have important roles in the development of oligodendrocyte lineage cells. Transition from
one stage to the next does not usually involve the loss of only one marker and
acquisition of another one. So it is a unique pattern, rather than a single component, that
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divides the path of oligodendrocyte differentiation into distinct phenotypic stages (Figure
1).

Oligodendrocyte transcription factor 1 (Olig1) and 2 (Olig2) and several members of the
Sry-related HMG box (Sox) family are the earliest markers of oligodendrocyte lineage
(Lu et al, 2000; Zhuo et al, 2000; Takebayashi et al, 2000; Stolt et al, 2002; Britsch et al,
2001; Kuhlbrod et al, 1998). Olig2 is also expressed by motor neuron precursors and is
critical for generation of both OPCs and motor neurons (Lu et al., 2002; Takebayashi et
al., 2002). Contrary to that, Olig1 is not essential for OPC production. Although its
transcription starts less than a day after that of Olig2 (Zhou et al, 2000), it has been
shown to play roles in oligodendrocyte development postnatally and is important for
oligodendrocyte maturation and myelination in the CNS (Lu et al, 2002; Xin et al, 2005).
Olig2 is a likely candidate that induces expression of Sox10 (Kuhlbrodt et al. 1998; Zhou
et al, 2000; Stolt et al, 2002), which is likely the first transcription factor that marks cells
committed to oligodendrocyte lineage (Kuhlbrod et al, 1998) and is critical for their
differentiation into myelinating oligodendrocytes (Stolt et al, 2002). The expression of
Olig1, Olig2 and Sox10 will persist throughout all stages of oligodendrocyte
differentiation.

The most widely used markers for OPCs are PDGFRA and chondroitin sulphate
proteoglycan 4 (CSPG4, NG2). Pdgfra transcript first appears at least one day upon
initial specification of OPCs and is most likely induced by Sox family of transcription
factors (Lu et al, 2000; Zhou et al, 2000; Tekki-Kessaris et al, 2001; Finzsch et al, 2008).
NG2 expression follows that of PDGFRA, on cells that have exited the VZ (Nishyama et
al, 1996; Zhu and Nishiyama; 2013). NG2 and PDGFRA will be coexpressed by OPCs
as they migrate away from the VZ, but will be coordinately downregulated as the
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progenitors differentiate (Nishiyama et al, 1996; Keirstead et al, 1998; Dawson et al,
2003).

As OPCs differentiate, they start expressing lipid antigens recognized by monoclonal
antibodies O4 and O1. A population of O4 positive cells coexpresses NG2 and PDGFRA
(Reynolds and Hardy, 1997). As OPCs transition to the stage of early (immature,
premyelinating) oligodendrocyte, they lose the expression of NG2 and PDGFRA and the
ability to proliferate and acquire the expression of galactocerebroside (GC, GalC)
recognized by O1 antibody (Gard et al, 1990).

Myelin

basic

protein

(MBP),

myelin

associated

glycoprotein

(MAG),

myelin

oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein (PLP) are classical
markers expressed by mature oligodendrocytes and myelinated axons. MBP, MAG and
PLP appear sequentially both in vitro (Dubois-Dalcq et al, 1986) and in vivo (Monge et
al, 1986).
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Figure

1.

Markers

that

identify

different

stages

of

oligodendrocyte

differentiation. Although not expressed exclusively by OPCs, but also by motoneuron
precursors, Olig2 is the first marker of oligodendrocyte lineage cells. It is followed by
Olig1 and Sox10, which expression will persist throughout an entire lineage. PDGFRA
and NG2 are the most commonly used markers for OPCs that are downregulated as
OPCs mature. As OPCs mature, they acquire the expression of O4 antigens, which is
followed by O1 antigens and CNP. Late (mature) oligodendrocytes are identified by the
expression of MBP, MAG, PLP and MOG, which appear in sequential manner.	
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Role of OPCs in rem yelination 	
  

In response to a variety of insults to the CNS, OPCs become activated and undergo
morphological changes, such as hypertrophy of the cell body and processes as well as
increase in proliferation (Levine et al, 1994, Keirstead et al, 1998; Nishiyama et al, 1997;
Di Bello et al., 1999; Levine and Reynolds, 1999). If the insult is directed towards
oligodendrocytes resulting in their damage and death, OPCs will repopulate the
oligodendrocyte-deprived areas and differentiate into oligodendrocytes in order to
compensate for their loss (Tripathi et al, 2010; Zawadzka et al, 2010).

MS is an autoimmune disease of the CNS, characterized by inflammation, demyelination
and astogliosis (Charcot, 1868; Frohman et al, 2006). Although axonal degeneration
occurs in MS (Ferguson et al, 1997), oligodendrocytes and myelin are the principal
targets of the inflammatory process. In the early stages of the disease, acute
demyelination is associated with remyelination (Gledhill, 1973). However, long-standing,
chronic lesions are not remyelinated efficiently (Keirstead and Blakemore, 1999).
Although the source of remyelinating oligodendrocytes in MS remains unclear, studies
have revealed the presence of OPCs in and around demyelinating lesions of MS (Wilson
et al, 2006). Adult OPCs are shown to be the cells that generate oligodendrocytes
following experimental demyelination in rodents in both acute (Zawadzka et al, 2010)
and chronic (Tripathi et al, 2010) models of demyelination. In fact, acute demyelinating
lesions are efficiently repaired (Zawadzka et al, 2010). Studies have implied that
remyelination is not limited by an absence of OPCs in demyelinating lesions, but may be
the result of OPC inability to differentiate into myelinating oligodendrocytes (Kuhlman et
al, 2008). Current MS treatments focus on the immunomodulation of the inflammatory
component of the disease and little progress has been made toward therapies that
11	
  

promote the regenerative process of remyelination. However, this would be a highly
effective complement to the immunomodulatory drugs.

Regulation of OPC proliferation and differentiation by PDGF

Oligodendrocyte differentiation in culture is regulated by various growth factors, such as
platelet derived growth factor (PDGF), fibroblast growth factor (FGF), ciliary neutrophic
factor (CNTF) CNTF and triiodothyronine (T3) (Barres et al, 1994; Noble et al, 1988; Raff
et al, 1985; Raff et al, 1988). However, a large body of evidence shows that PDGF is the
key regulator of OPC proliferation and differentiation both in vitro and during
development (van Heyningen et al, 2001). Numerous studies have confirmed that PDGF
is a major mitogen for OPCs (Noble and Murray, 1984; Noble et al, 1988; Richardson et
al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff et al, 1988;
Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988). PDGF promotes survival
(Barres et al, 1992), division and motility (Noble, 1988) of OPCs. At the same time,
PDGF signaling has been shown to inhibit OPC differentiation in vitro and its withdrawal
from the culture medium is sufficient to trigger OPC differentiation (Raff et al, 1985; Raff
et al, 1988; van Heyningen et al, 2001). Early studies on the effect of PDGF on OPCs
proposed that PDGF drives an “internal clock”	
   that counts cell divisions and regulates
the timing of OL development in culture (Raff et al, 1985; Raff et al, 1988). However
some of the later studies suggested that in the presence of PDGF, OPCs can divide
indefinitely (Barres et al, 1994). Although it is evident that PDGF has an important role in
regulation of OPC differentiation, its role is more complex than a simple on/off switch
and is still incompletely understood.
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In vivo, PDGF is most likely produced by astrocytes (Raff et al, 1985; Richardson et al,
1988) and neurons (Yeh et al, 1991). Its presence in the rodent CNS throughout
gliogenesis (Richardson et al, 1988; Pringle et al, 1989) suggests its role in the control of
OPC differentiation and myelination in vivo. Its importance is further supported by the
evidence that aberrant PDGF expression in vivo can altar OPC survival, proliferation and
timing of their differentiation (Calver et al, 1998; Fruttiger et al, 1999).

A family of PDGFs includes 4 isoforms, named PDGFA, B, C and D. All isoforms are
secreted as disulfide-linked bivalent ligands that can form both homomers and
heteromers. PDGFs exert their effect through their receptors, PDGFRA and B. Ligand
binding induces receptor dimerization, trans-phosphorylation and the activation of signal
transduction cascades (reviewed by van der Geer et al, 1994).

Several other growth factors have also been shown to influence oligodendoroglial
development in vitro, including insulin like growth factor 1 (McMorris et al, 1986;
McMorris and Dubois-Dalcq, 1988), epithelial growth factor (EGF) (Sheng et al, 1989)
and basic FGF (Eccleston and Silberg, 1985; Saneto and de Vellis, 1985, Besnard et al,
1989).

PDGFRA and its expression during developm ent

The only PDGFR isoform expressed by OPCs is PDGFRA. Since in the CNS, PDGFRA
is expressed predominately by OPCs (Pringle et al, 1992), it has become one of the
most commonly used markers for OPCs (Pringle et al, 1989; McKinnon et al, 1990;
Nishiyama et al, 1996; Dawson et al, 2003). PDGFRA is expressed by OPCs both in
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vivo (Hart et al, 1989) and in vitro (Hart et al, 1989; McKinnon et al, 1990) and is rapidly
downregulated in OPCs that start to differentiate (Hart, 1989; Hall, 1996).

PDGFRA is expressed early during development and is one of the earliest markers that
label cells committed to oligodendrocyte lineage. In the mouse CNS, the first expression
of PDGFRA is detected around E11, in a restricted region of ventral neuroepithelium
(Spassky et al, 1998). In the rat CNS, the first PDGFRA transcripts appear around E13
and it are also restricted to a distinct region of vetral neuroepithelium (Pringle and
Richardson, 1993; Pringle et al, 1996). The first PDGFRA-expressing cells appear as
distinct focus, which then spreads out indicating OPC migration away from the VZ.
PDGFRA expression persists in migrating OPCs, but also those that have settled to
brain parenchyma. OPCs in the adult brain continue to express PDGFRA.

Similar to PDGF, PDGFRA is critical for OPC development and differentiation. PDGFRA
disruption in OPCs results in their premature differentiation in culture, whereas OPCs
from PDGFRA hemizygous mice show impaired proliferation and accelerated maturation
(McKinnon et al, 2005). Together with the studies that indicate that PDGFRA ligand
inhibits OPC differentiation (Raff et al, 1985; Noble et al, 1988; Raff et al, 1988; van
Heyningen et al, 2001), McKinnon study suggests the default pathway that OPCs
undertake is differentiation. This pathway is normally inhibited by PDGFRA signaling in
progenitor cells and signaling through PDGFRA needs to be repressed in order for
OPCs to differentiate. Since PDGFRA is present in OPCs, but gets downregulated as
OPCs differentiate, it is likely that PDGFRA and its downregulation are critical factors
that control oligodendrocyte differentiation and that PDGFRA has to be downregulated in
order for OPCs to differentiate. However, molecular mechanisms that lead to
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transcriptional repression of PDGFRA and therefore trigger differentiation remain to be
defined.

PDGFRA regulation

The molecular mechanisms governing the transcription of PDGFRA are poorly
understood. PDGFRA gene lacks a typical TATA box. A number of transcription factors
were shown to regulate PDGFRA transcription in cells that do not belong to
oligodendrocyte lineage, such as ubiquitously expressed NFkB (Kitami et al, 1995;
Lindros et al, 1998), C/EBP (Fukuoka et al, 1999; Kitami et al, 1999), Sp1 and Sp3
(Khachigan et al, 1994; 1995; 1996; Bergeron et al, 2011), but only few transcription
factors were shown to directly regulate PDGFRA transcription in OPCs.

FGF has been shown to positively regulate PDGFRA transcription, maintain high levels
of PDGFRA expression and inhibit OPC differentiation (McKinnon et al, 1990) but the
signaling pathway involved in this regulation is still unclear. Its role in oligodendrocyte
development is likely complex and involves other signaling mechanisms and
transcription factors since it has been shown that FGF can regulate PDGFRA
transcription both positively (McKinnon et al, 1990) and negatively (Bonello et al, 2004).

SoxE family of transcription factors is critical for oligodendrocyte development (Stolt et
al, 2002; 2003). PDGFRA expression starts with a delay relative to that of Sox9 and
Sox10 and it is likely that these two transcription factors have a role in the regulation of
PDGFRA transcription during OPC development. Sox9 has been shown to directly bind
to PDGFRA gene and positively regulate its expression (Finzsch et al, 2008).
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Transcription factor Nkx2.2 is expressed in OPCs in the developing mouse spinal cords
and plays an essential role in the terminal differentiation of oligodendrocytes (Qi et al.,
2001; Zhou et al., 2001). In addition, Nkx2.2 is upregulated in OPCs immediately before
their differentiation, but rapidly downregulated upon their differentiation (Fu et al., 2002;
Soula et al., 2001; Xu et al., 2000; Zhou et al., 2001). Its role in oligodendrocyte
development might involve regulation of PDGFRA expression since Nkx2.2 has been
shown to directly bind to the 5’	
  region of PDGFRA and repress its transcription (Zhu et
al, 2014).

Posttranscriptional regulation of genes by small noncoding RNAs has become an
evident factor playing part in many physiological and pathological processes (reviewed
by Stefani and Slack, 2008). Micro RNAs (miRNAs) are a class of small noncoding
RNAs that are negative regulators of gene expression at the posttranscriptional level.
They act either through inhibition of translation or degradation of their target RNAs and
are able to regulate multiple targets simultaneously (reviewed by Flynt and Lai, 2008).
Micro RNAs have been shown to play critical role in the development of neurons
(Visvanathan et al, 2007; Cheng et al, 2009) and oligodendrocytes (Dugas et al, 2010;
Zhao et al, 2010). One of these miRNAs, miR-219, is induced during OPC differentiation
and targets negative regulators of differentiation. Its overexpression promoted, while its
knockdown inhibited OPC differentiation (Dugas et al, 2010; Zhao et al, 2010). In
addition, miR-219 has been shown to directly bind to Pdgfra mRNA and regulate its
expression (Dugas et al, 2010).
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Drug discovery

Discovery and design of new therapeutic chemicals and their development into
medicines consists of several steps and each has its challenges. The initial difficulty in
this process arises in the discovery of the lead compound. The lead is a prototype that
has a number of attractive characteristics (desired biological activity) but may have other
undesirable characteristics (toxicity, insolubility, metabolism).

Two types of approaches can be taken to identify the lead and they are based on
random and nonrandom discovery. The first requirement for both approaches is to have
ways of assaying compounds for desired biological activity. An assay (screen) is done in
a biological system and can be done both in vitro and in vivo. In vitro assays are quicker
and less expensive. High throughput screens (HTS) can be carried out robotically in 96,
384 or 1536 well plates with as little as submicrogram amounts of compound dissolved
in submicroliter volume. With this approach, it is possible to screen 100,000 compounds
in a day. HTS appears to have resulted in an increase in the number of hits, but has not
been resolved yet whether this increase in the hit rate translates to a greater number of
leads.

Nonrandom screen is performed when the lead has already been discovered. This is
more focused screen aimed towards compounds that have resemblance to the lead
compound discovered in random screen. Compounds used for nonrandom screens
might have only vague structural resemblance to the lead. Even if the lead was shown to
be only mildly active, screen can uncover lead derivatives that are more potent.
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In the absence of known leads with desired activity, a random screen is a valuable
approach. This type of screen involved a large number of compounds of various
chemical structures. All compounds are screened in the bioassay without regard to their
structures. Prior to 20th century, this was essentially the only approach because not
many leads were known. Today, this is still an important approach particularly because it
is now possible to screen huge numbers of compounds rapidly with HTS. This is also the
lead discovery method of choice when nothing is known about the receptor target.

Neither random nor nonrandom screens involve rational approaches. However, rational
approaches that involve designing a compound that has a particular biological activity
have become an important route in lead discovery. Many diseases are caused by
imbalance of particular chemicals in the body. Proteins, such as growth factors,
receptors, enzymes, transcription factors or other members of signaling pathways, are
common cause for the disruption of the homeostasis of a biological system. This
imbalance can be corrected by agonism/antagonism of a receptor or activation/inhibition
of an enzyme. However, for this kind of approach, it is critical to know which protein is
responsible for this imbalance. This is sometimes difficult to achieve due to complex
physiological responses that might be caused by disruption of balance.

Drug m odifications

Upon discovery of the lead compound, its structure is modified by chemical synthesis to
amplify the desired activity and to minimize or eliminate the unwanted properties. Even if
the lead had only weak biological activity, its derivatives might be more potent. Structure
modifications are the keys to activity and potency manipulations. Activity is the particular
biological effect, while potency is the strength of that effect.
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Interactions of drugs with their targets are very specific. Therefore, only a small part of
the lead, called pharmacophore, may be involved in the interaction. Other residues,
called auxophores, are also important because they may maintain the integrity of the
drug, hold the pharmacophore in the correct position or stabilize the interaction between
pharmacophore and its target. Some residues might have a negative effect and might be
interfering or destabilizing the interaction. It is important to find out what residues are
critical for drug action and what need to be removed and this can be determined by
chemically excising different portions of the lead.

In addition to removal of residues that have negative effect on compounds potency,
addition of certain residues and structural modifications of the lead can improve lead’s
physicochemical properties. Such properties include: size, shape, electronic distribution,
lipid solubility, water solubility, chemical reactivity or hydrogen bonding. As a
consequence, lead manipulations may cause changes in of the following effects.
Structural –	
   holding of other functionalities in a particular geometry, shape or hydrogen
bonding. Target interactions –	
  interaction with the target. Pharmacokinetics –	
  absorption,
transport or excretion of the compound. Metabolism –	
   blocking or aiding metabolism.
Since these changes and their effects can reflect on compounds potency in both positive
and negative manner, multiple modifications may often be necessary to balance the
effect.

Solubility of compound is one of the critical features that can greatly affect compound
potency. For each drug to be active, it needs to interact with two environments –	
  
aqueous (extracellular space and cytoplasm) and lipophilic (membranes, such as cell
membrane of blood brain barrier). Low lipophilicity is a great obstacle because it causes
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poor permeability through membranes. Increased lipophilicity improves compound’s
permeability and therefore, its accessibility to the target. However, highly lipophilic
compounds are not efficiently transported through the hydrophilic extracellular media
and are easily metabolized, which limits their availability. Therefore, there needs to be a
fine balance between drug’s lipophylicity and hydrophilicity, this depends on compound
structure and can be achieved by modifying the lead.

Adding or excising CH2 groups can greatly affect drug properties. For many compounds,
lengthening of a saturated carbon side chain up to nine results in an increase in
compound potency, while further lengthening causes sudden decrease in potency. This
is associated with increased lipophilicity of the molecule until its lowered water solubility
becomes its dominant feature. Chain branching decreases lipophilicity and lowers
potency, but may also interfere with interaction of the pharmacophore and its target.
Ionization and low pH lead to increased water solubility since under these conditions,
compounds’	
   residues are protonated and can participate in forming hydrogen bonds
more easily.

Bioisosteres are substituents that have similar physicochemical and biological
properties. This is an important lead modification that can fine-tune compound’s
metabolism, toxicity and potency. One of the common bioisosteric modifications is the
replacement of hydrogen atom with fluorine at a site of metabolic oxidation in a lead may
prevent such metabolism from taking place. Because the fluorine atom is similar in size
to the hydrogen atom the overall topology of the molecule is not significantly altered,
leaving the desired biological activity unaffected. However, with a blocked pathway for
metabolism, the drug candidate may have a longer half-life.
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Structure-activity relationships (SARs)

Structure-activity relationship (SAR) is relationship of the molecular structure of the
compound and its biological activity. The analysis of SARs provides another way to
reveal pharmacophore and auxophores.

The hallmark of SAR studies is the synthesis of as many analogs as possible of the lead
and their testing to determine the effect of structure on activity or potency. Once enough
analogs are made and tested, conclusions can be made regarding SAR. Ease of
synthesis rather than logic rationale is often the guiding force behind the choice of
analogs made.

Upon identifying the critical chemical groups, structure of the lead compound can be
additionally manipulated in a rationale manner in order to further increase its potency.
Biological properties of a compound are often a function of its physicochemical
parameters, such as solubility, lipophylicicty, ionization, stereochemistry, etc. Therefore,
it is possible to correlate compound structure to its biological effect. This can be used to
direct the synthesis of lead derivatives.

PDGF signaling in m alignancies

Tumors arising from glial cells (gliomas) are the most common forms of primary tumors
of the CNS. They are among the most deadly types of cancers, but the malignancy
grade is an essential factor in predicting patient’s outcome. Grade I tumors are treatable.
However, by the time it is diagnosed, tumor might have progressed to higher grade
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when even with the most invasive procedures that combine surgery, radiation and
chemotherapy, patient’s prognosis is weak.

Hyperactivation of RTK signaling pathways is a frequent hallmark of malignant gliomas,
EGF/EGFR being the most common. Aberrant PDGF signaling has also been
associated with the development of different types of malignancies, including those
occurring in the CNS (Hermanson et al, 1992; Di Rocco et al, 1998; Martinho et al, 2009;
Ozawa et al, 2010; Heldin, 2013). Based on the expression profile, glioblastomas have
been classified into several categories and mutations of EGFR and PDGFRA define the
classical and proneural subtypes, respectively (Vehaak et al, 2010). Although PDGFRA
mutations are not as common as those of EGFR, this still makes PDGFR the second
most frequently mutated RTK gene in glioblastoma (The Cancer Genome Atlas
Research Network, 2008). Amplification is the most commonly observed PDGFRA gene
alteration, while point mutations, deletions and gene rearrangements are rare and occur
more frequently in glioma samples that already have PDGFRA amplification (Martinho et
al, 2009; Verhaak et al, 2010; Ozawa et al, 2010). In addition, the expression pattern of
PDGF and PDGFRs suggest the presence of autocrine and paracrine stimulatory loops,
which may contribute to tumor progression (Hermanson et al, 1992).

Growing knowledge on the contribution of PDGF signaling in cancer development and
progression has led to different kinds PDGF signaling inhibitors that target either PDGFs
of PDGFRs. Antibodies and soluble extracellular parts of the receptors can intervene
with PDGF signaling by binding to PDGFs or PDGFRs, prevent their interaction or
promote their degradation (Hawthorne et al, 2008; Shen et al, 2009). However, they are
expensive and difficult to administer. Small molecule inhibitors of PDGFR are attractive
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candidates for cancer therapy and are clinically explored (Morris and Abrey, 2010;
Paulsson et al, 2011). One of the first and most promising drugs, imatinib, has been
used in the treatment of several cancers (Iqbal and Iqbal, 2014). However, it was shown
to be unsuccessful in the treatment of CNS malignancies (Reymond et al, 2008), which
might be due to its limited penetration through the blood brain barrier (Takayama et al,
2002; Senior, 2003). In addition, imatinib, as well as other small molecule inhibitors, was
shown to have a broader spectrum of targets, which may contribute to drug’s side effects
(reviewed by Heldin, 2013).

Small molecule inhibitors, which are currently used for treatment of cancers driven by
aberrant RTK signaling or evaluated as potential therapies, are directed toward inhibiting
kinase activity of respective RTKs and were shown to be non-specific. Targeting specific
RTKs by regulating their expression instead of kinase activity might complement current
therapies. In addition, design of novel small molecules that are able to cross blood brain
barrier might provide significant contribution to the treatment of CNS malignancies.
Since PDGFRA is one of the two most frequently mutated genes in gliomas and since
PDGFRA signaling pathway plays an important role in tumor development, PDGFRA
represents a good candidate for targeted therapy. Downregulating its expression at the
mRNA level might lead to reduction in proliferation of PDGFRA-expressing cells, which
may limit tumor progression and improve patient’s survival.
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Chapter 2	
  – Identification of sm all m olecule com pounds that dow nregulate the
transcription of PDGFRA in m ouse oligodendrocyte progenitor cell line 	
  

Introduction

PDGFRA signaling is the key regulator of OPC proliferation and differentiation. PDGFRA
transcription is first detected in a distinct area of VZ early during development (at E11E13 in the rodent CNS) and is one of the earliest markers that label cells of
oligodendrocyte lineage. PDGFRA expression persists in OPCs that have migrated
away from the subventricular zone and have settled in brain parenchyma. However, as
OPCs differentiate, PDGFRA gets rapidly downregulated (Hart, 1989; Hall, 1996).

Change in transcription is generally the earliest event that occurs during differentiation.
Regardless whether downregulation of Pdgfra transcription is the cause or consequence
of differentiation, we used this change as an indicator of decrease in proliferation and
increase in differentiation caused by small molecule compounds.

To identify compounds that downregulate Pdgfra transcription we used random screen.
Compounds were purchased as stocks distributed in 96-well plates. They were tested
with an assumption that each plate contained compounds of different and random
structure. Compounds were tested on Oli-neu cells, which represent mouse
oligodendrocyte precursor cell line. We performed three screens in parallel. Luciferase
assay was used to indirectly evaluate changes in Pdgfra transcription. In addition to
quantitative luciferase assay screen, we performed qualitative immunocytochemistry and
morphology based screens to examine whether compounds promote Oli-neu cell
differentiation or inhibit their proliferation. We next verified Pdgfra downregulation by
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assaying the level of endogenous Pdgfra transcript upon treatment with the most
promising candidate compounds.

Our results revealed a group of small molecule compounds, which structure is derived
from the lead N-methyl-N-benzylguanidine, that downregulate luciferase activity of
Pdgfra plasmid in a dose-response manner and inhibit transcription of endogenous
Pdgfra.

Methods

Cell culture

Oli-neu cells, which represent mouse oligodendrocyte precursor cell line (Jung et al,
1995), were used for the primary screen as well as verification of hit compounds. Oli-neu
cells were grown on poly-L-lysine-coated culture dishes. Cells were maintained in growth
medium consisting of Dulbecco's Modified Eagle Medium/Ham's F-12 (DMEM/F12)
(Invitrogen) supplemented with 1% horse serum (Hyclone SH30074.03), N2 supplement
(Invitrogen), 100 U/ml penicillin and 100 µg/ml streptomycin. Addition of 1 mM dibutyryl
cyclic adenosine 3,5-monophospahte (dbcAMP) (Jung et al, 1995) or dexamethasone
(DEX) (Joubert et al, 2010) has been shown to induce differentiation of Oli-neu cells
towards mature oligodendrocytes. To induce differentiation of Oli-neu cells, dbcAMP
(Sigma) and DEX (Sigma) were added to the culture medium, to 1 mM and 10 μM final
concentration, respectively.
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Plasmids
Plasmids were obtained by polymerase chain reaction (PCR), using DNA purified from
the RP23-412J9 BAC clone as the template and primers listed in table 1. For the
plasmids PR-111, PR-336, PR-1000 and PR-1595, KpnI and SacI restriction sites
(underlined in the primer sequence) were incorporated into the forward and reverse
primers, respectively, to facilitate the cloning of the resulting PCR fragment into the
pGL4.10 vector (Promega). In order to generate PR-2229 plasmid, XhoI restriction site
was incorporated into the reverse primer, while the internal SacI site, located 2229
nucleotides upstream from the TSS, was used for digestion of the PCR fragment at the
5’	
   end. Plasmids were purified with Plasmid Midi Kit (QIAGEN) and the insert position
and its sequence was confirmed by sequencing using vector backbone primers (vector
backbone forward primer: GCTGTCCCCAGTGCAAGTGCAGG and vector backbone
reverse primer: AGTGGGTAGAATGGCGCTGGGCC).

Transfections and luciferase assays

Transfections

were

carried

out using

Lipofectamine

(Invitrogen)

according

to

manufacturer’s instructions. The day before transfection, cells were seeded in 24-well
tissue culture plates. They were transiently co-transfected with 0.75 μg of the test
plasmid and 0.05 μg of pGL4.73 vector (Promega) to control for differences in
transfection efficiencies. As negative control, we used pGL4.10 vector that had no
Pdgfra insert, while pGL3 promoter (Promega) was used as positive control. Cells were
split the next day to 96-well plates in order to make triplicates. After allowing cells to
adhere for 4-6h, they were induced to differentiate. Two days after induction of

26	
  

differentiation, the cells were lysed and the luciferase activities were assessed using a
DualGlo Luciferase Assay kit (Promega).

Plasmid name	
  

Primer sequence	
  

Restriction site	
  

Forward primer	
  

CCGGTACCCAGAGAGCAAGGAGTCCTAGGG

Kpn I	
  

Reverse primer	
  

CCGAGCTCCTCTCCCTCAAGCTCCAACAG	
  

Sac I	
  

Forward primer	
  

CCGGTACCCACCCCCAAATTGGGAAGTC	
  

Kpn I	
  

Reverse primer	
  

CCGAGCTCCTCTCCCTCAAGCTCCAACAG	
  

Sac I	
  

Forward primer	
  

CCGGTACCTTGGTTCCTGGAGTGTCAGC	
  

Kpn I	
  

Reverse primer	
  

CCGAGCTCCTCTCCCTCAAGCTCCAACAG	
  

Sac I	
  

Forward primer	
  

CCGGTACCGTGCAAGCCTGTTCGCAGAC	
  

Kpn I	
  

Reverse primer	
  

CCGAGCTCCTCTCCCTCAAGCTCCAACAG	
  

Sac I	
  

Forward primer	
  

GACACCCTGGGTTGAGTGAC	
  

Sac I (internal)	
  

Reverse primer	
  

GGCTCGAGCTCTCCCTCAAGCTCCAACAG	
  

Xho I	
  

PDGFRA-111	
  

PDGFRA-336	
  

PDGFRA-1000	
  

PDGFRA-1595	
  

PDGFRA-2229	
  

Table 1. Primers used to make plasmids containing 5’	
   Pdgfra sequences of different
lengths. Plasmid name indicates the position of the starting nucleotide and is relative to
the transcription start site of the Pdgfra gene. All primers, except the forward primer
used to make PR-2229, incorporate restriction enzyme digestion sites used to facilitate
cloning. The position of these sites is underlined.
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Small molecule compounds

A library of small molecule compounds for the primary screen was purchased from
Chembridge as 96-well mother plates (plate identification: NT 1147 30941 through NT
1147 30957) with compounds dissolved in dimethyl sulfoxide (DMSO) as 5 mM stocks.
Compounds were located in columns 2 through 11 of the 96-well plate, while columns 1
and 12 contained DMSO and were used as control. Upon identification of potential
leads, 5 mg of each compound was purchased from Hit2Lead and dissolved in DMSO in
order to make 50 mM stocks.

Luciferase assay screen

Transfections of Oli-neu cells were carried out using Lipofectamine (Invitrogen)
according to manufacturer’s instructions. The day before transfection, cells were seeded
in 6-well tissue culture plates (1.5 million cells/well). They were transiently co-transfected
with 3.5 μg of PDGFRA-luc plasmid and 0.5 μg of pGL4.73 (Promega) to control for
differences in the transfection efficiency. Day after transfection, Oli-neu cells were split to
flat bottom 96-well plates (10,000 cells/well). One well of the 6-well plate would usually
yield sufficient number of cells for one 96-well plate. Cells were allowed to adhere for 46h when compounds were added at 50 μM concentration. Two days later, DualGlo
Luciferase Assay (Promega) was performed.
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Morphology and immunocytochemistry screen

Oli-neu cells were seeded in flat bottom, clear 96-well plates (10000 cells/well). They
were let to adhere for 4-6h when compounds were added to the final concentration of 25
μM. Medium was not replaced during the incubation time and no fresh compound was
added. After 4 days, cells were examined under the light microscope and any changes in
cell morphology and/or changes in cell density were noted. Oli-neu cells were then fixed
in wells using 95% ethanol 5% glacial acetic acid and immunostained using O1 antibody.
Cells were observed with Zeiss Axiovert microscope.

RNA isolation, reverse transcription and quantitative PCR

Oli-neu cells were plated in 6-well plates and treated with selected small molecule
compounds at 50 μM concentration for 2 days. Total RNA was collected from 500,000
cells using RNeasy Mini Kit (QIAGEN). An aliquot of the total RNA (1 μg) was then used
as a template to synthesize cDNA using Superscript III (Invitrogen and according to
manufacturers recommendations. Quantitative PCR (qPCR) was performed using SYBR
Green PCR Master Mix (Life Technologies). For each reaction, we used 10 ng of cDNA
and gene-specific primers listed in table 2. The PCRs were done using the following
conditions: 2 min at 95°C followed by 39 cycles of denaturation (10s at 95°C), annealing
and extension (30s at 60°C). The specificity of PCR products was confirmed by the
analysis of the melting curve. Quantification of gene expression was first normalized to
GAPDH and then expressed as a logarithm of the ratio of treated to control mRNA level.
Each amplification reaction was performed three independent times.
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Gene	
  

Forward primer	
  

Reverse primer	
  

Gapdh	
  

TGACAACTTTGGCATTGTGG

ATGCAGGGATGATGTTCTGG	
  

Pdgfra	
  

TCGAAGGCAGGCACATTTAC	
  

TTGAGTCTCCGGATCTGTGG	
  

Fgfr1	
  

CTAACCGCAGAACTGGGATG	
  

TGGACCAGGAGAGACTCCAC	
  

Fgfr3	
  

TGCACAAGGTCTCTCGCTTC	
  

TCAGCAGGCAGCTCAAGTTC	
  

Table 2. Primers used for quantification of mRNA in Oli-neu cells in control conditions
and upon treatment with 50 μM selected compounds. All primers span adjacent exons
and their specificity was confirmed by melting curve.
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Results 	
  

Identification of the PDGFRA-luc plasm id for the screen

In order to identify the most suitable plasmid that we would use in the luciferase
screening assay, we cloned various lengths of the mouse Pdgfra 5’	
   flanking sequence
into the pGL4.10 vector, which contains cDNA encoding firefly luciferase (FF) (Figure 2.
A). We next transfected these plasmids into Oli-neu cells and induced the cells to
differentiate towards oligodendrocytes using 1 mM dbcAMP and 10 μM DEX. Plasmid
that contains cDNA for renilla luciferase (R) driven by SV40 promoter and enhancer
(pGL4.73) was used as internal control. As negative control, we used pGL4.10 vector
that had no Pdgfra insert, while pGL3 promoter (Promega), that contains firefly luciferase
cDNA driven by SV40 promoter, was used as positive control. DualGlo Luciferase Assay
was performed two days after induction of differentiation. Plasmid PR-1595, that
contains 1595 nucleotides of the Pdgfra 5’	
   flanking sequence, showed the highest
luciferase activity and the most robust response to differentiation conditions decreasing
its activity by ~35%. This plasmid was used for the screen and will be refer to as
PDGFRA-luc (Figure 2. B).

To identify compounds that inhibit OPC proliferation and stimulate their differentiation,
we performed 3 primary screens in parallel: luciferase assay, immunocytochemistry
(ICC) and morphology screens. These screens were all done in Oli-neu cells.
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Figure 2. Identification of the PDGFRA-luc plasm id for the screen. Various
lengths of the 5’	
   sequence of mouse Pdgfra gene (black lines) were cloned into the
pGL4.10 vector 5’	
  to firefly cDNA (white box). The number in the plasmid name indicates
the position of the most 5’ nucleotide of the included insert relative to Pdgfra
transcription start site (TSS), which is indicated as +1 (A). Upon transfection of Oli-neu
cells and induction of their differentiation, PR-1595, which contains 1595 nucleotides of
the Pdgfra 5’	
   sequence, showed the highest luciferase activity under control conditions
and the most robust response to differentiation conditions, decreasing its activity by 35%
(B). This plasmid will be referred to as PDGFRA-luc. # p < 0.001 relative to pGL4.10
control, * p < 0.001 relative to control, two-way ANOVA, Bonferroni posttest. Error bars
are standard deviations of the mean.	
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Luciferase assay screen

Since Pdgfra downregulation is associated with a decrease in OPC proliferation and
their differentiation, we used changes in Pdgfra transcription to select for compounds
that downregulate Pdgfra transcription indirectly, by luciferase assay.

To identify compounds that downregulate PDGFRA-luc activity, we transfected Oli-neu
cells with PDGFRA-luc and pGL4.73, split them to 96-well plates and treated them with
small molecule compounds for 2 days at 50	
   μM concentration before performing
luciferase assay.

We tested approximately 1500 compounds in several batches so that 80 (1 plate), 160
(2 plates) or 320 (4 plates) compounds were tested at the same time. To eliminate dayto-day variation between experiments, each batch of samples was analyzed at the same
time, but independently from other batches. Firefly luciferase was normalized to renilla,
and averages and standard deviations of each batch were determined. To compare
different batches of samples, normalized luciferase values were converted to standard
scores (Z scores) using values for averages and standard deviations for each batch of
samples.

Our results show that out of 1500 compounds tested, 931 downregulated PDGFRA-luc
activity below the mean. Treatment with 87 compounds resulted in Z score value below
-1 while 14 compounds had Z scores below -2. None of the compounds had Z score
below -3. Contrary to that, 589 compounds upregulated PDGFRA-luc activity above the
mean. Out of these, 125 compounds caused standardized PDGFRA-luc activity to be
greater than 1, 60 compounds had Z scores above 60, while 33 compounds had Z
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scores above 3 (Figure 3. A). For further evaluation, we selected compounds that
resulted in Z score values of -1 and below.
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Figure 3. Screening for com pounds that prom ote Oli-neu cell differentiation.
For the luciferase assay based screen, Oli-neu cells were transfected with PDGFRA-luc
and treated with small molecule compounds at 50 μM for 2 days. Each black dot
represents standardized (Z score) PDGFRA-luc activity normalized to internal control. All
compounds that downregulated PDGFRA-luc activity by more than Z = -1 (Z score
values below the dashed blue line) were selected for further evaluation. Z score =
(normalized PDGFRA-luc activity –	
   mean)/SD (A). For morphology and ICC based
screens, Oli-neu cells were seeded to 96-well plates and treated with small molecule
compounds at 25 μM. After 4 days, they were examined for the changes in morphology
and/or density (C). ICC for O1 revealed compounds that increased the expression of O1
and/or the percentage of O1+ cells (B). Venn diagram summarizes the results of the 3
screens: 87 compounds downregulated PDGFRA-luc activity (blue), 146 caused
changes in Oli-neu cell morphology and/or density (green) and 179 caused an increase
in the O1 expression and/or the percentage of O1+ cells (red) (D).	
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Morphology and im m unocytochem istry screen 	
  

In addition to quantitative luciferase assay-based screen, we performed qualitative ICCand morphology-based screens. Oli-neu cells were plated in 96-well plates and treated
with 1500 small molecule compounds at 25	
   μM concentration. After 4 days, we
examined cell morphology and noted any morphological changes that could indicate
differentiation (elongation or increased branching of processes) or decrease in the
proliferation rate (decrease in cell density). Each compound was scored (Figure 3. C).
Oli-neu cells were then fixed in the same plates and immunostained for O1, a more
mature marker of oligodendrocyte lineage. We noted and scored compounds that
caused an increase in the O1 expression, assessed as brightness of the staining relative
to control, and/or the percentage of O1 positive (O1+) cells (Figure 3. B). Out of 1500
compounds, 146 caused a change in Oli-neu cell morphology and/or decrease in their
density, while 179 compounds caused an increase in the O1 expression and/or the
percentage of O1+ cells. Results of the three screens were summarized (Figure 3. D)
and all candidate compounds were scored and ranked.

It should be pointed out that since morphology and ICC-based screens were performed
and analyzed independently from luciferase assay screen, some of the candidate
compounds identified in these two screens turned out to be upregulators of PDGFRA-luc
activity. We need to keep in mind that morphology and ICC-based screens were
performed under different conditions. Most importantly, Oli-neu cells were treated with
compounds over a longer period of time. Luciferase assay screen detects early changes
in gene transcription and PDGFRA upregulation could have caused an increase in cell
survival or initial increase in their proliferation. Primary OPCs were shown to have
density-dependent control of proliferation (Zhang et al, 1996) and it is possible that a
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similar mechanism exists in Oli-neu cells. Being an immortalized line, Oli-neu cells have
a high rate of proliferation that persists over long period of time. However, with
prolonged or irregular passaging that causes their overgrowth, there might be changes
in the pattern of expression of several relevant markers, such as O1 (unpublished
observations).

Verification of luciferase assay screen

From the rank list of all candidate compounds, we selected the top 20 to verify
downregulation of PDGFRA-luc activity by performing dose-response assays. Similarly
to the initial luciferase assay screen, Oli-neu cells were transfected with PDGFRA-luc
and pGL4.73 and split to 96-well plates the day after transfection. We made serial
dilutions of stock compounds and treated Oli-neu cells at concentrations ranging from 10
nM to 1 mM. Cells were treated for 2 days when luciferase assay was performed. All
compounds were citotoxic at 1000 mM and many were citotoxic at 316 μM. Due to
compound toxicity, assessed either by examining cell morphology or based on the low
values for renilla luciferase activity measured in the luciferase assay, not all data points
were included in the dose-response curves. We analyzed dose-response curves and
determined half maximal inhibitory concentrations (IC50) using GraphPad Prism.

Out of 20 candidates tested, 7 were confirmed and downregulated PDGFRA-luc activity
in a dose-response manner. Out of these 7 compounds, 3 had similar chemical structure
(39D11, 40A10 and 40B10). They were derivatives of the lead N-methyl-Nbenzylguanidine (guanidine compounds). The 4th guanidine compound (39E11) altered
Oli-neu cell morphology and decreased their density, but it caused a modest dose
dependent decrease in PDGFRA-luc activity. The remaining 4 compounds, that
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downregulated PDGFRA-luc activity, were not structurally related to each other or to
guanidine compounds (Figure 4). IC50 for these 8 compounds were shown in Table 3.

Compound	
  

IC50 range (mM)	
  

39D11	
  

Very wide	
  

40A10	
  

0.01643 to 0.07563	
  

40B10	
  

0.02634 to 0.08656	
  

39E11	
  

Very wide	
  

42E8	
  

Very wide	
  

54G2	
  

0.001429 to 0.004847	
  

44C8	
  

2.974*10-5 to 9162	
  

45C11	
  

3.167*10-7 to 66571	
  

Table 3. Half maximal inhibitory concentrations for compounds that were verified in the
dose-response assay. Oli-neu cells were treated with indicated compounds at
concentrations ranging from 10 nM to 1 mM. Luciferase assay was performed after 2
days of treatment. GraphPad Prism was used to create and analyze dose-response
curves. However, due to compound toxicity assessed by examining cell morphology
under light microscope and renilla luciferase activity, not all data points were included in
the dose-response curves. Half maximal inhibitory concentrations (IC50) were
deterimend using GraphPad Prism.	
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Figure 4. Verification of the candidate com pounds. Oli-neu cells were transfected
with PDGFRA-luc and pGL4.73 and treated with top 20 candidate compounds selected
from primary screens. Graphs show normalized luciferase activity as a response to
different concentrations of compounds. Out of 20 candidates tested, 7 downregulated
PDGFRA-luc activity in a dose-response manner. Out of these 7 compounds, 3 (39D11,
40A10 and 40B10) had similar chemical structure based off the lead N-methyl-Nbenzylguanidine (top). Although the 4th derivative of N-methyl-N-benzylguanidine
(39E11) altered Oli-neu cell morphology in the morphology-based screen, it showed a
modest dose response effect on PDGFRA-luc downregulation (top). Remaining 4
compounds, that also resulted in dose-dependent downregulation in PDGFRA-luc
activity, were not structurally related to N-methyl-N-benzylguanidine or to one another
(bottom).	
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Verification of endogenous Pdgfra transcription dow nregulation 	
  

Since PDGFRA-luc plasmid contains luciferase cDNA and only a portion of the mouse
Pdgfra gene, downregulation of its activity upon treatment with guanidine compounds
might not be an accurate reflection of the changes in endogenous Pdgfra transcription.
Therefore, we examined changes in endogenous Pdgfra mRNA level upon treatment of
Oli-neu cells with guanidine compounds. Oli-neu cells were seeded in 6-well plates and
treated with 50 μM compounds for 2 days. As assessed by qPCR, Pdgfra mRNA level
was ~15 fold lower compared to DMSO control. To the contrary, Pdgfra transcription was
comparable to DMSO control when cells were treated with 42E8, a non-guanidine
compound that caused dose-response in PDGFRA-luc activity. We also analyzed the
changes in mRNA levels of two additional receptor tyrosine kinases (RTKs) expressed
by OPCs. Changes in transcription for Fgfr1 and Fgfr3 were far less robust compared to
those of Pdgfra. Compounds 39D11 and 39E11 caused a modest decrease in the level
of Fgfr1 transcript, while treatment with 40A10 and 40B10 resulted in a marginal
increase. Contrary to downregulation of Pdgfra transcription, Fgfr3 transcription was
upregulated upon treatment with guanidine compounds. Fgfr3 transcript level increased
by approximately 2.5 fold relative to DMSO control (Figure 5). These results suggest that
downregulation of transcription by guanidine compounds is specific for Pdgfra, and it
does not occur with other RTKs, such as Fgfr1 and Fgfr3.
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Figure 5. Changes in endogenous transcription upon treatm ent w ith guanidine
com pounds. Oli-neu cells were treated with guanidine compounds at 50 μM for 2 days
when RNA was collected and analyzed. Results of qPCR showed ~15 fold decrease in
mRNA level of Pdgfra. To the contrary, the transcript level of Fgfr1 showed only marginal
change, while that of Fgfr3 increased by ~2.5 fold. Each bar represents the average
result obtained from 3 independent experiments. Error bars are standard errors of the
mean. (A = amplification factor; dCtC = delta Ct of DMSO control; dCtT = delta Ct upon
treatment with compounds)	
  

45	
  

Discussion 	
  

Results of the primary screens revealed candidate compounds that caused PDGFRA-luc
downregulation in Oli-neu cells and may have promoted their differentiation. There were
11 compounds that met our criteria in all three primary screens: they downregulated
PDGFA-luc activity, caused an increase in O1 expression and altered cell morphology.
However, 61 compounds met only two out of three criteria. This implies that
downregulation of PDGFRA-luc does not necessarily correlate with acquisition of mature
phenotype. This makes sense because it is unlikely that PDGFRA-luc contains all the
regulatory elements necessary for OPC-specific expression of Pdgfra gene. This is
further supported by the results obtained during identification of the most suitable
plasmid for the screen. Although treating Oli-neu cells with inducers of differentiation
resulted in a decrease in PDGFRA-luc activity, this decrease was only ~35%.

Although luciferase assay has its flaws, such as incomplete regulatory sequences and
introduction of foreign cDNA into the cell, it is fast and efficient and as such, it represents
a very useful tool for screening. It would be more informative to run two luciferase assay
screens in parallel, first using PDGFRA-luc and second utilizing regulatory elements of
an early oligodendrocyte gene, such as Cnp, which gets upregulated as OPCs
differentiate into mature oligodendrocytes. A great improvement to the technique would
be to use stable instead of transient transfections, where the firefly luciferase cDNA is
driven by regulatory elements of endogenous Pdgfra gene expressed by Oli-neu cells.

Oli-neu cells are immortalized cell line derived from primary mouse OPCs. Although it
has been shown they are able to generate MAG-expressing cells (Jung et al, 1995), we
were unable to push them down the oligodendrocyte differentiation pathway further than
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O1-expressing cell. Contrary to that, a study by Pereira et al (2011) suggests that Olineu cells are father along the differentiation pathway compared to N20.1 cells, which
represent immortalized oligodendroglial cell line (Verity et al, 1993; Newman et al, 1995;
Pereira et al, 2011). Whether Oli-neu cells represent immature progenitor cell or early
oligodendrocyte, this may contribute to low responsiveness of PDGFRA-luc to inducers
of differentiation. With numerous transgenic mouse lines available, using primary OPCs
from transgenic mice that have fluorescent reporter driven by endogenous genes of
oligodendrocyte lineage might provide a better biological system to detect differentiating
OPCs.

To select candidate compounds after the luciferase assay screen, we calculated
averages and standard deviations of each batch of samples and selected compounds
that caused PDGFRA-luc downregulation by at least 1 SD below the average. Using SD
assumes normal distribution, which does not seem to be the case in our experiment.
Compounds that caused robust upregulation of PDGFRA-luc activity skewed the
distribution in their favor. Therefore, this criterion is arbitrarily determined in order to
establish a cutoff.

Morphology based screen revealed compounds that resulted in a decrease in Oli-neu
cell density relative to DMSO control or altered their morphology towards a more
differentiated phenotype. Although the selected compounds might have a desired effect
inhibiting Oli-neu cell proliferation of promoting their differentiation, we did not run
consecutive experiments to verify their effect. Therefore, we need to keep in mind that
the decrease in cell density might be due to partial cytotoxicity of compounds. Similarly,
change in cell morphology might be caused by cytoskeleton reorganization that is not
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directly related to differentiation. Therefore, these results need to be interpreted with
caution and in perspective with results obtained from luciferase assay and ICC screens.

Only 7 out of 20 candidates tested were verified in a dose-response assay. Compounds
based on N-methyl-N-benzylguanidine structure were further verified with respect to their
effect on endogenous Pdgfra transcription. A robust downregulation observed in the
level of Pdgfra transcript contrasts those of Fgfr1 and Fgfr3. This implies that the effect
of compounds is specific for pathway that regulates Pdgfra transcription and not to those
that regulate Fgfr1 or Fgfr3 transcription.
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Chapter 3. Determ ine structure activity relationship for com pounds that
dow nregulate Pdgfra transcription in Oli-neu cells

Introduction

Drug discovery, especially the one based on random screen, usually does not yield in
identifying the drug that meets all the criteria we have established. These criteria
include, but are not limited to (1) desired biological activity, (2) high potency and (3) no
toxicity. Instead, what is likely to be discovered is the compound that has the desired
activity, but might have unwanted properties, such as low potency or some degree of
toxicity. This compound is called “the lead”. After lead has been identified, it is important
to determine the relationship between leads’	
   derivatives and their biological activity
(structure-activity relationship, SAR). By examining multiple lead derivatives, it is
possible to find out which residues are critical for maintaining drug properties and which
can be removed or replaced in order to increase drug potency and diminish its toxicity.
Determining SAR is often performed by synthesizing as many lead derivatives as
possible and their testing for biological activity and potency. Structure modifications of
the lead can be done rationally because compound properties are often based on its
physicochemical properties, such as solubility and lipophylicity. However, it is usually the
ease of synthesis that prevails when determining what structure modifications will be
made. Once sufficient derivatives are tested, conclusions can be drawn regarding SAR.

In order to determine SAR for guanidine derivatives, we first performed structure-based
screen on an entire Chembridge library, identified all guanidine compounds that were
included in the library and related their structure to the biological effect they showed in
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our primary screen. We next synthesized (courtesy of Michael VanHeyst and Dr. Dennis
Wright) 12 additional guanidine derivatives and tested their effect on PDGFRA-luc
activity and Pdgfra transcription.

Results of the SAR analysis suggest that the critical positions for modifications of the
lead N-methyl-N-benzylguanidine, which are required for its biological effect, are
carbons 2 or 3 of the benzyl ring. Addition of either methyl group or chlorine to carbons 2
or 3, as well as methoxy group to carbon 2, greatly increases the potency of the lead.
Elongation of the carbon chain between the nitrogen atom and benzyl ring results in an
increase in lead’s potency even without the additional modifications.

Methods

Screening

Structure-based screening of the Chembridge library was done using Instant JChem
5.9.0, 2012 downloaded from ChemAxon website (http://www.chemaxon.com). Library
was uploaded to Instant JChem and screened based on N-methyl-N-benzylguanidine
structure.

Guanidine derivatives

Our collaborators, Michael VanHeyst and Dr. Dennis Wright, from the Department of
Pharmaceutical Sciences synthesized 12 guanidine derivatives that were used in this
study. Compounds were dissolved in DMSO and their purity was tested using Nuclear
magnetic resonance (NMR) spectroscopy.
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We also examined and compared NMR

spectra of newly synthesized compounds to that of compounds purchased from
Chembridge.

Luciferase assay

Luciferase assay was done as described in Chapter 3 (Methods). Briefly, Oli-neu cells
were seeded to 6-well plate and transfected with PDGFRA-luc and pGL4.73. They were
split to 96-well plate the following day and treated with guanidine compounds for 2 days
at 3 μM and 30 μM.

RNA isolation, reverse transcription and quantitative PCR

RNA isolation, reverse transcription and qPCR were done as described in Chapter 3
(Methods). Briefly, Oli-neu cells were treated with guanidine compounds for 2 days at 50
μM. RNA was purified using RNeasy Mini Kit (QIAGEN). An aliquot of 1 μg RNA was
used for cDNA synthesis using Superscript III (Invitrogen) and 10 ng cDNA was used for
each qPCR using SYBR Green PCR Master Mix (Life Technologies). Quantification of
gene expression was first normalized to GAPDH and then expressed as a logarithm of
the ratio of treated to control mRNA level. Primers used for qPCR: Gapdh (forward 5’TGACAACTTTGGCATTGTGG,
(forward

5’-

reverse

5’-ATGCAGGGATGATGTTCTGG)

TCGAAGGCAGGCACATTTAC,

TTGAGTCTCCGGATCTGTGG).
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reverse

Pdgfra
5’-

Results 	
  

Structure-based screen for derivatives of N-m ethyl-N-benzylguanidine

Chembridge library contains approximately 100,000 compounds. However, only a small
portion of approximately 1,500 compounds from the library was used for the primary
screens in our study. Structure-based screen of Chembridge library revealed only 9
guanidine derivatives (Figure 6). These compounds were distributed between 2 mother
plates and both plates happened to be selected for the primary screens. Out of these 9
compounds, 5 did not show the desired biological effect in any of the primary screens.
On the other hand, 3 compounds (39D11, 40A10 and 40B10) met the criteria in all 3
primary screens. The remaining compound (39E11) did not cause decrease in
PDGFRA-luc activity in the luciferase assay screen, but did cause decrease in Oli-neu
cell density and change in their morphology.

Analysis of SAR suggests that N-methyl-N-benzylguanidine (compound 39C11) is
necessary, but not sufficient to induce desired biological activity by itself. Methyl group or
chlorine potentiates the effect of N-methyl-N-benzylguanidine. However, this occurs only
if one of these residues is present on either carbon 2 (C2) or carbon 3 (C3) of the benzyl
ring (Figure 6).

Guanidine com pounds dow nregulate PDGFRA-luc activity

In order to further examine the relationship between the differences in structures of
guanidine compounds and their activity, our collaborators Michael VanHeyst and Dr.
Dennis Wright from the Department of Pharmaceutical Sciences generated 12 guanidine
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derivatives, arbitrarily named 001 through 012 (Figure 7. A). The effect of these
compounds was tested in luciferase assay (Figure 7. B). Oli-neu cells transfected with
PDGFRA-luc and pGL4.73 were treated with guanidine compounds at 2 concentrations
that matched 2 data points of previously established dose-response curves (Figure 4).
None of the compounds caused significant downregulation of PDGFRA-luc activity at 3
μM relative to control. Different potency of these compounds was more evident when
Oli-neu cells were treated with higher concentration of compounds. At 30 μM, 002 and
008 were the most potent and caused significant and most robust downregulation of
PDGFRA-luc, while 009, 010, 011 and 012 did not downregulate PDGFRA-luc activity.
Compounds 003, 004, 005 and 007 caused a significant downregulation of PDGFRA-luc,
although this effect was less robust compared to that of 002 and 008. Finally, treating
Oli-neu cells with 006 resulted in a marginal decrease in PDGFRA-luc activity that did
not reach significance. (Figure 7. B). Although structurally identical, 001 and 40A10, as
well as 007 and 40B10, did not show the same potency. Therefore, our collaborators
compared the purity of compounds 40B10 and 007 by NMR spectrometry. NMR
spectrum showed that 40B10 contained traces of an unknown chemical, which might be
responsible for the more robust effect of 40B10 relative to 007 (not shown).

SAR analysis revealed that replacing benzyl ring with pyridine abolished the biological
effect of the compound. Compound 005 had stronger effect compared to 007. Therefore,
the choice of the residue that will be added to C3 of the benzyl ring appears to be
important in increasing compound’s potency, methyl group being the better choice than
chlorine. Compound 008 was one of the 2 derivatives that showed the most robust
downregulation of PDGFRA-luc, which indicates that elongating the guanidine side chain
increases potency. Finally, addition of methoxy group to C2 of the benzyl ring
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(compound 002) results in very robust biological effect. However, if methoxy group is
placed on C3 of the same ring (compound 006), compound’s potency is drastically
decreased. Compounds 009, 010, 011 that have pyridine in place of benzyl, as well as
012 that has 2 methoxy groups on C3 and C4 did not alter PDGFRA-luc activity. This
might be due to increased polarity of these compounds.
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Figure 6. Structure-based screen for guanidine com pounds. Chembridge library
has approximately 100,000 small molecule compounds out of which only 9 are N-methylN-benzylguanidine derivatives. 39D11, 39E11, 40A10 and 40B10 were selected for
verification after the primary screens, whereas remaining compounds did not alter either
PDGFRA-luc activity, Oli-neu cell morphology or O1 expression. Selected 4 compounds
had either methyl group or chlorine on C2 or C3 of the benzyl ring.	
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Figure 7. Structure and potency of guanidine derivatives. Our collaborators from
the Department of Pharmaceutical Sciences synthesized 12 guanidine derivatives (A,
courtesy of Micheal VanHeyst and Dr. Dennis Wright). Oli-neu cells were transfected
with PDGFRA-luc and pGL4.73 and treated with newly generated compounds for 2 days
at 3 or 30 μM when relative luciferase activity was measured. None of the compounds
caused significant downregulation of PDGFRA-luc activity at 3 μM. At 30 μM, it was
evident that compounds have different potencies. Treatment with compounds 002 and
008 resulted in the most robust downregulation of PDGFRA-luc, while compounds 009,
010, 011 and 012 did not alter PDGFRA-luc activity. Although structurally identical, 007
and 40B10 had different potencies (B). Each bar in panel B represents average
PDGFRA-luc activity normalized to internal control and presented relative to DMSO
control (100%). * p < 0.05 relative to control, one sample t-test.	
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Guanidine com pounds dow nregulate endogenous Pdgfra transcription 	
  

Results of the luciferase assay suggest that newly generated guanidine compounds
downregulate Pdgfra transcription. The next question we asked was whether different
potency of compounds would be reflected on Pdgfra transcript levels in the same
manner that was observed in the luciferase assay. To answer this question, we selected
5 compounds (002, 005, 006, 008 and 012) that had different potency when previously
tested in the luciferase assay. Compounds 002 and 008 were shown to be the most
potent in the luciferase assay, while 005 caused significant but less robust effect.
Compounds 002 and 006 were positional isomers that showed drastically different
downregulation of PDGFRA-luc, while 012 did not alter PDGFRA-luc.

To determine whether endogenous Pdgfra transcription will follow the trend observed in
the luciferase assay, Oli-neu cells were treated with selected compounds at 50 μM for 2
days when RNA was collected and analyzed by qPCR. As expected, changes in Pdgfra
transcript levels (Figure 8. A) reflected those previously observed in the luciferase assay
(Figure 8. B). Compounds 002 and 008 caused the most robust decrease in Pdgfra
transcript levels, while 005 was less potent. Compounds 006 and 012 did not alter
Pdgfra transcript level.

We also compared the potencies of Chembridge and compounds synthesized by our
collaborators with respect to their effect on endogenous Pdgfra transcription. Similarly as
in the luciferase assay (Figure 7), commercial compounds showed greater potency in
the qPCR assay. Chembridge compounds caused a decrease in the Pdgfra transcript
level between 10 and 16 fold, while compound 002, the most potent compound
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generated in Dr. Dennis Wright’s lab, decreased Pdgfra transcript level by less than 9
fold. Structurally identical 005 and 39E11 also had dramatically different potencies.
Treatment with 005 resulted in ~3 fold decrease in Pdgfra transcript level, while that with
39E11 decreased Pdgfra transcript level by ~11 fold (Figure 8. A and C).
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Figure 8. Changes in endogenous transcription upon treatm ent w ith guanidine
com pounds. Oli-neu cells were treated with compounds 002, 005, 006, 008 and 012
(A) or guanidine compounds purchased from Chembridge (C) when RNA was collected
and changes in Pdgfra transcription were analyzed by qPCR. Changes in Pdgfra mRNA
levels (A) reflected those observed in the luciferase assay (B). Treatment with
compounds 002 and 008 resulted in the most robust decrease in Pdgfra transcript level,
while that with 005 was moderate. Compounds 006 and 012 did not alter Pdgfra
transcription (A). Commercial compounds however were shown to be more potent
compared to compounds generated in Dr. Dennis Wright’s lab (C). In panels A and C,
each bar represents the average result obtained from 3 independent experiments. Error
bars are standard errors of the mean. dCtC = delta Ct of DMSO control; dCtT = delta Ct
upon treatment with compounds. In panel B, each bar represents average PDGFRA-luc
activity normalized to internal control and presented relative to DMSO control. The
experiment was done in triplicates and error bars are standard deviations. * p < 0.05,
one sample t-test.

62	
  

Discussion 	
  

Structure based screen of Chembridge library followed by SAR analysis revealed that Nmethyl-N-benzylguanidine is necessary, but not sufficient to induce desired biological
activity. Addition of methyl group or chlorine potentiates the lead’s effect, but the position
of these 2 residues is critical. Improvement in compound’s potency occurs only if either
methyl group or chlorine is present on either C2 or C3 of the benzyl ring. It would be
interesting to see whether compound’s potency would be further improved if both C2 and
C3 were occupied by either 2 methyl groups or 2 chlorines or a combination of methyl
group and chlorine (Figure 9).

SAR analysis of 12 additional derivatives synthesized by our collaborators revealed
several other pieces of information. (1) Compound 007 showed slightly more robust
effect compared to that of compound 001 which suggests that addition of chlorine at C3
instead at C2 of the benzyl ring might be a better choice improving compound’s potency.
(2) We could not synthesize positional isomer for compound 005 that would have methyl
group at C2 instead at C3 but the potency of these 2 isomers would be interesting to
compare. (3) Since compound 004 showed greater potency relative to that of compound
003, this suggests that removal of methyl group from the nitrogen might further
potentiate compound’s effect. (4) Presence of methoxy group at C2 (compound 002)
greatly improves compound’s potency, but this does not happen if the same residue is
present at C3 (compound 006). (5) Compound 008 is drastically more potent compared
to 003. This suggests that elongating the chain between guanidine and benzyl ring by
one carbon might be a critical modification. Such modification might exert its effect by
increasing compound lipophylicity, stabilizing the compound-target interaction or
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facilitating the interaction between the pharmacophore and the receptor. Based on SAR
analysis of Chembridge and compounds generated by our collaborators, we propose
further modifications that include a combination of selected residues and predict such
modifications would increase the potency of guanidine compounds (Figure 9).

Replacement of hydrogen atom with fluorine may extend compound’s half-life if such
replacement was done at the site of metabolic oxidation. Because the fluorine atom is
similar in size to the hydrogen atom, the overall topology of the molecule is not
significantly altered, leaving the desired biological activity unaffected. Although structure
based screen revealed 3 compounds that had such modifications, we did not perform an
experiment

to

assess

N-methyl-N-benzylguanidine

stability

and

whether

such

modifications would improve it. However, this is something that needs to be kept in mind
once the top candidates are tested for their biological effect in vivo.

The effect that guanidine compounds exerted on Pdgfra transcript level generally
followed a similar trend to that observed in the luciferase assay. Compound 002 was the
most potent in both assays, while 012 did not cause a change in Pdgfra transcription or
PDGFRA-luc activity. Changes in transcription upon treatment with compounds 005 and
008 also reflected those observed in the luciferase assay. We were surprised to notice
treatment with 006 did not alter Pdgfra transcript level although it did cause modest
decrease in PDGFRA-luc activity that did not reach significance. In addition, for qPCR
assay, cells were treated with compounds at 50 μM while the highest concentration used
in the luciferase assay was 30 μM.

64	
  

In both luciferase assay and qPCR assay, commercial compounds were shown to be
more potent compared to those synthesized by our collaborators. Compounds 005 and
007 are structurally identical to 39E11 and 40B10, respectively. However, their effects
on PDGFRA-luc and Pdgfra transcription are drastically different. We examined and
compared purities of compounds 007 and 40B10 and identified traces of an unknown
chemical, which might be responsible for the difference in the effect we have observed.
It would be interesting to identify this chemical or separate it from N-methyl-N-(3chlorinebenzyl) guanidine using column chromatography and analyze its effect
independently from guanidine compound. Although we did not compare the purities of
compounds 005 and 39E11, it is likely 39E11 contains compound other than N-methylN-(3-methylbenzyl) guanidine. Whether this is true as well as the nature of
contaminating compound remains to be identified.
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Figure 9. Predicted structural m odifications of N-m ethyl-N-benzylguanidine
that w ould result in its increased potency. SAR analysis of Chembridge and
compounds synthesized by our collaborators revealed that the following modifications of
N-methyl-N-benzylguanidine increase its potency: addition of methyl group or chlorine to
C2 or C3 of the benzyl ring, addition of methoxy group to C2, removal of the methyl
group from the nitrogen atom of the guanidine group and elongation of the carbon chain
between the nitrogen atom of the guanidine group and benzyl ring. We predict that a
combination of such modifications, generating structures shown in this figure, would
result in a further increase in N-methyl-N-benzylguanidine potency. Such modifications
are illustrated on this figure. Addition of a residue (chlorine, methyl or methoxy group) to
the carbon atom of N-methyl-N-benzylguanidine is indicated by an arrow, removal of the
methyl group from the nitrogen atom is indicated by an arrowhead, while asterisk marks
elongation of the carbon chain.	
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Chapter 4	
  – Determ ine w hether the com pounds prom ote OPC differentiation.	
  

Introduction

PDGF signaling is the major regulator of OPC proliferation and differentiation. Studies
have implied that it has to be inhibited in order for OPC differentiation to occur (Noble et
al, 1988; McKinnon et al, 2005). In vitro, this can be achieved by PDGF removal from the
culture medium (Raff et al, 1985; Raff et al, 1988) or blockage with anti-PDGF antibodies
(Richardson et al, 1988; Noble et al, 1988). In vivo, PDGF knockout results in decreased
number of OPCs (Fruttiger at al, 1999). OPCs from PDGFRA knockout mice undergo
accelerated maturation and the onset of differentiation appears to depend on the Pdgfra
gene dose (McKinnon et al, 2005). PDGFRA is rapidly downregulated as OPCs
differentiate (Hart, 1989; Hall, 1996) and we used the downregulation of its transcription
as putative indicator of differentiation.

Here, we wanted to examine whether guanidine compounds, identified in the primary
screen and verified as downregulators of Pdgfra transcription in Oli-neu cells, promote
Oli-neu and OPC differentiation. To answer this question, we used Oli-neu cells and
dissociated culture of primary rat OPCs and examined the changes in transcription of
OPC- and oligodendrocyte-specific genes upon treatment with guanidine compounds.
We also examined whether treatment of primary rat OPCs with guanidine compounds
would result in an increase in the percentage of differentiating identified by O1 antibody.
Our results show that, although compounds cause a decrease in the level of Pdgfra
transcript, they are do not upregulate transcription of more mature markers of
oligodendrocyte lineage or the percentage of O1+ primary rat OPCs.
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Methods

Dissociated cultures of primary rat OPCs

Mixed glial cultures were prepared as descried previously (Yang et al, 2005). Briefly,
cerebral cortices from P2-P4 CD rats (Charles River Laboratories) were dissected out,
minced, triturated and plated in 75 cm2 culture flasks coated with 30 μg/ml poly-L-lysine
(Sigma). Cell cultures were maintained in Dulbecco's Modified Eagle Medium (DMEM)
(Gibco 11960) containing 10% FBS (Gibco 26140) at 37°C in humidified air with 5%
CO2. After 6-8 days, loosely attached cells were shaken-off and preplated for 30
minutes in order to eliminate contaminating astrocytes and microglia from cells of
oligodendrocyte lineage. The non-adherent cells were collected, resuspended in
immunopanning buffer containing Dulbecco's phosphate-buffered saline (DPBS) (Gibco
14287), 0.02% bovine serum albumin (BSA) (Sigma A-4161), 5 μg /ml insulin (Sigma I6634), and plated in petri dishes coated with monoclonal O1 antibody in order to
separate mature oligodendrocytes from OPCs. Cells that did not adhere to the dish were
collected and plated in petri dishes coated with O4 monoclonal antibody. Purified OPCs
were resuspended in Sato’s medium: DMEM (Gibco 11960), 2 mM L-glutamine (Gibco
25030), 1X penicillin/streptomycin (Gibco 15140), 100 μg/ml transferrin (Sigma T-1147),
100 μg/ml BSA (Sigma A-4161), 16 μg/ml putrescine (Sigma P-5780), 60 ng/ml
progesterone (Sigma P8783), 40 ng/ml sodium selenite (Sigma S5261), 5 μg/ml N-acetyl
cysteine (Sigma A8199), 1 mM sodium pyruvate (Gibco 11360), 1X trace elements B
(Cellgro 99-175-CI), 10 ng/ml D-biotin (Sigma B4639), 5 μg/ml insulin (Sigma I-6634), 5
μM forskolin (Sigma F6886), 10 ng/ml CNTF (Peprotech 450-13), 1 ng/ml neutrophin 3
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(NT3) (Peprotech 450-03). OPCs were then plated in poly-L-lysine coated tissue culture
plates in the medium containing 20 ng/ml mouse PDGF (Peprotech 100-13A).

Immunocytochemistry

After positive selection of O4-expressing OPCs, cells were resuspended in Sato’s
medium and were plated in poly-L-lysine coated tissue culture plates in medium
containing 20 ng/ml mouse PDGF (Peprotech 100-13A). They were allowed to
proliferate for 2 days when they were trypsinized and split to coverslips coated with 100
μg/ml poly-L-lysine at the density of 5,000 cells/coverslip. They were kept in medium
containing 5 ng/ml mouse PDGF (Peprotech 100-13A). For differentiation experiments,
either T3 (Sigma T6397) or compounds were added to the final concentration of 400
ng/ml and 10 μM, respectively. They were treated for 2 days before fixing with 4%
paraformaldehyde (PFA) and staining for O1.

RNA isolation, reverse transcription and quantitative PCR

RNA isolation, reverse transcription and qPCR for transcripts expressed by Oli-neu cells
were done as described in Chapter 3 (Methods). Briefly, Oli-neu cells were treated with
guanidine compounds for 2 days at 50 μM. RNA was purified using RNeasy Mini Kit
(QIAGEN). An aliquot of 1 μg RNA was used for cDNA synthesis using Superscript III
(Invitrogen) and 10 ng cDNA was used for each qPCR using SYBR Green PCR Master
Mix (Life Technologies). Quantification of gene expression was first normalized to
GAPDH and then expressed as a logarithm of the ratio of treated to control mRNA level.
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Primary rat OPCs used for qPCR were obtained from P4 rat cortices by
immunoselection using anti-O1 and goat anti-mouse PDGFRA antibodies. After
selection of PDGFRA expressing cells, OPCs were resuspended in Sato’s medium
supplemented with 20 ng/ml mouse PDGF (Peprotech 100-13A), plated in poly-L-lysine
coated tissue culture plates and allowed to proliferate for 3 days. Approximately 50% of
medium was removed every day and replaced with 50% of fresh culture medium. On the
3rd day, OPCs were trypsinized and resuspended in Sato’s medium that contained 5
ng/ml mouse PDGF. They were split to poly-L-lysine coated tissue culture dishes. To
promote differentiation, either 400 ng/ml T3 or 10 μM 39D11 were added to the culture
medium. Cells were treated for 2 days before RNA was extracted from approximately
250,000 cells using RNeasy Mini Kit (QIAGEN). An aliquot of 1 μg RNA was used for
cDNA synthesis using Superscript III (Invitrogen) and 10 ng cDNA was used for each
qPCR using SYBR Green PCR Master Mix (Life Technologies). The PCRs were done
using the following conditions: 2 min at 95°C followed by 39 cycles of denaturation (10s
at 95°C), annealing and extension (30s at 60°C). Quantification of gene expression was
first normalized to GAPDH and then expressed as a logarithm of the ratio of treated to
control mRNA level.
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Gene	
  

Forward primer	
  

Reverse primer	
  

Mouse Gapdh	
  

TGACAACTTTGGCATTGTGG

ATGCAGGGATGATGTTCTGG	
  

Mouse Pdgfra	
  

TCGAAGGCAGGCACATTTAC	
  

TTGAGTCTCCGGATCTGTGG	
  

Mouse Cspg4	
  

GGCCTTGTTGGTCAGATCTACAG	
  

GCAGCAGGTCTACTCTGGTCAGA	
  

Mouse Olig2	
  

TTACAGACCGAGCCAACACC	
  

GATGGGCGACTAGACACCAG	
  

Mouse Sox10	
  

TACCCTCACCTCCACAATGC	
  

AGTCCGGATGGTCCTTTTTG	
  

Mouse Cnp	
  

GCCAGGTCTTTCTGGAGGAG	
  

TTGTACAGTGCAGCACACCTG	
  

Mouse Mbp	
  

ACACACGAGAACTACCCATTATGG	
  

TGTTCGAGGTGTCACAATGTTCTT	
  

Mouse Gfap	
  

GATCTATGAGGAGGAAGTTCGAGAA	
   CGTATTGAGTGCGAATCTCTCTCA	
  

Rat Gapdh	
  

TAGAGACAGCCGCATCTTCTTG	
  

CGTTGATGGCAACAATGTCC	
  

Rat Pdgfra	
  

TTGGAGCTTGAGGGAGTGAAAC	
  

AGACAGCTGAGGACCAGAAAGG	
  

Rat Cspg4	
  

TTACAAGTCCAGACGCCCAAC	
  

GTTCTCCCCGAAGAAGGAGG	
  

Rat Mbp	
  

AAATCGGCTCACAAGGGATTC	
  

AGGATTCGGGAAGGCTGAG	
  

Table 4. Primers used for quantification of mRNA in Oli-neu cells and primary rat OPCs
in control conditions and upon treatment with guanidine compounds. All primers span
adjacent exons and their specificity was confirmed by melting curve.	
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Antibodies	
  

Immunoselection of primary rat OPCs for immunocytochemistry was done with the
following antibodies: secondary antibody used for coating petri dishes was goat antimouse IgM μ chain specific in 50mM Tris-HCl pH 9.5 (Jackson Immunoresearch 115005-020) at 1 μg/ml in, while the primary antibodies were mouse anti-O1 and anti-O4
supernatant obtained from Dr. S. Pfeiffer (Farmington, CT) at 1:1 dilution in PBS with
0.2% BSA. For immunostaining, we used mouse anti-O1 (Dr. S. Pfeiffer) at 1:1 dilution in
PBS with 5% normal goat serum (NGS) and Cy3 conjugated donkey anti-mouse IgM, µ	
  
chain specific (Jackson Immunoresearch 715-165-020). Immunoselection of primary rat
OPCs for qPCR was done with the following antibodies: secondary antibody used for
coating petri dishes was donkey anti-goat IgG (Jackson Immunoresearch 705-006-147),
while the primary antibody was goat anti-mouse PDGFRA (R&D Systems). Antibodies
were dissolved in 50 mM Tris-HCl pH 9.5 at 1 μg/ml.

Results

Guanidine com pounds do not prom ote differentiation of prim ary rat OPCs

Results of the primary screen indicated that guanidine compounds cause an increase in
O1 expression and change Oli-neu cell morphology towards a more mature phenotype.
Therefore, we hypothesized that they will also promote differentiation of primary OPCs.
To test this hypothesis, we used primary rat OPCs purified from neonatal rat cortices.
OPCs were plated on coverslips in the medium that contained 5 ng/ml PDGF. They were
treated with 10 μM compounds on the same day, while addition of 400 ng/ml T3 to the
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culture medium was used as positive control. After 2 days, cells were fixed and stained
for O1. Under differentiating conditions (medium supplemented with T3), the percentage
of O1+ cells increased by approximately 3 fold. In addition, O1+ cells acquired different
morphology. While O1+ cells under control conditions were small and had short
processes, ones treated with T3 had longer and more branched processes as well as
lamellipodia. Several guanidine compounds caused a change in OPC morphology,
which resembled that observed when cells were treated with T3, but the length and
branching of processes was less extensive compared to the T3 control (non-quantified
observations). However, although several compounds caused an increase in the
percentage of O1+ cells, this increase did not reach significance (Figure 10. B).

Changes in transcription occur before progenitor cells acquire differentiated phenotype.
Although treatment with guanidine compounds did not cause a significant increase in the
percentage of O1+ cells, we wanted to examine whether it would cause a change in
Pdgfra, Ng2 or Mbp transcript levels (Figure 10. C). Although Pdgfra transcript level
decreased upon treatment with 39D11, this decrease was marginal. Mbp transcript level
also showed a slight decrease, while that of Ng2 increased. Taken together, these
results do no support our hypothesis that guanidine compounds promote differentiation
of primary rat OPCs.

Guanidine com pounds do not upregulate transcription of m ore m ature
oligodendrocyte m arkers in Oli-neu cells

We used Oli-neu cells treated with 50 μM compounds for 2 days to analyze the
endogenous transcription of several genes which expression changes during OPC
differentiation. As OPC differentiate toward mature oligodendrocytes, Pdgfra and NG2
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transcription decreases, while that of Cnp and Mbp increases. Olig2 and Sox10 are
transcription factors that persist throughout an entire oligodendocyte lineage. Therefore,
their transcript levels would not show a dramatic change. When induced to differentiate,
Oli-neu cells were also shown to upregulate more mature markers of oligodendrocyte
lineage, such as Cnp, Mbp and Plp (Joubert et al, 2010). Our qPCR results showed that
Pdgfra transcript indeed follows the expected transcriptional changes when Oli-neu cells
were treated with guanidine compounds. All commercially available guandine
compounds caused a decrease in Pdgfra transcript level, while non-guanidine
compound (42E8) did not cause a change in transcription (Figure 11. A). Similarly to
Chembridge compounds, guanidine derivatives synthesized by our collaborators also
caused a decrease in Pdgfra transcription and showed different potencies (Figure 11. B).
However, Ng2 transcript level showed only marginal decrease when treated with
Chembridge compounds. Contrary to Chembridge compounds, treatment with 002, 005,
006 and 008 caused a slight increase in Ng2 transcription. Changes in Sox10 transcript
levels were similar to that of Ng2. Unexpectedly, Cnp transcription was decreased upon
treatment with guanidine compounds while that of Mbp was marginally decreased upon
treatment with Chembridge compounds and marginally increased upon treatment with
002, 005, 006 and 008. Surprisingly, Olig2 transcription was robustly inhibited when Olineu cells were treated with both sets of guanidine compounds (Figure 11. A and B).

When treated with FBS in culture, both primary OPCs and Oli-neu cells were shown to
downregulate OPC-specific genes and upregulate astrocyte genes. Therefore, we asked
whether guanidine compounds induce Oli-neu cell differentiation toward astrocytes,
rather than oligodendrocytes. The trend we observed examining transcript levels of OPC
and oligodendrocyte markers would support this hypothesis. Therefore, we looked at
changes in transcription of glial fibrillary acidic protein (Gfap), which is a commonly used
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marker for astrocytes (Bignami et al, 1972). Our qPCR results showed that compounds
002, 005, 006 and 008 caused a 2-fold increase in the Gfap transcript level (Figure 11.
B). However, when Oli-neu cells were treated with commercial compounds, Gfap
transcription was comparable to control (Figure 11. A). Taken together, these results
suggest that although guanidine compounds downregulate Pdgfra transcription, they do
not promote differentiation of OPCs to oligodendrocytes or astrocytes.
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Figure 10. Differentiation of prim ary rat OPCs upon treatm ent w ith guanidine
com pounds. Purified rat OPCs were treated with 10 μM compounds for 2 days before
they were immunostained for O1 (A). Quantification showed that addition of T3 resulted
in a significant increase in the percentage of O1+ cells among all cells. Although several
guanidine compounds caused a slight increase in the percentage of O1+ cells, this
increase was modest and did not reach significance. (C) Primary rat OPCs, maintained
in the medium that contained 5 ng/ml PDGF, were treated either with T3 or 39D11 at
400 ng/ml or 10 μM, respectively. After 2 days of treatment, RNA was collected and
changes in transcription were analyzed by qPCR. dCtC = delta Ct of DMSO control;
dCtT = delta Ct upon treatment with compounds. * p<0.05, two sample t-test relative to
control.	
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Figure 11. Changes in endogenous transcription upon treatm ent w ith
guanidine com pounds. Oli-neu cells were treated with 50 μM guanidine compounds,
which were either purchased from Chembridge (A) or synthesized by our collaborators
(B). After 2 days of treatment, RNA was collected and changes in transcription were
analyzed by qPCR. Each bar represents the average result obtained from 3 independent
experiments. Error bars are standard errors of the mean. dCtC = delta Ct of DMSO
control; dCtT = delta Ct upon treatment with compounds. 	
  

80	
  

Discussion 	
  

PDGFRA is rapidly downregulated as OPCs differentiate. Therefore, we hypothesized
that downregulation of Pdgfra transcription caused by guanidine compounds would
correlate with increase in Oli-neu and OPC differentiation.

Differentiation of OPCs was assessed by quantification of the percentage of O1+ cells,
qualitative examination of cell morphology and qPCR. Although there was a slight
decrease in the Pdgfra transcript level when cells were treated with 39D11, this
decrease was less than 2-fold. Surprisingly, Mbp transcript level was decreased as well,
but marginally. We did not observe a significant increase in the percentage of O1+ cells
with any of the compounds. Several guanidine compounds seemed to have caused a
change in cell morphology similar to that observed when OPCs were treated with T3 but
of far less extent. All this suggests that treatment with guanidine compounds is not
sufficient to induce differentiation of primary rat OPCs under the conditions we used.
PDGF has been shown to be a potent mitogen for OPCs but also suggested as an
inhibitor of their differentiation (Noble and Murray, 1984; Noble et al, 1988; Richardson
et al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff et al, 1988;
Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988). When OPCs are treated
with 10 ng/ml PDGF, they proliferate over a period of several days (Noble et al, 1988,
Richardson et al, 1988). However, upon PDGF withdrawal, they rapidly differentiate
(Raff et al, 1983; Noble, 1984; Temple, 1985). All this suggests that PDGF signaling
needs to be finely balanced in order for differentiation to occur under given conditions. It
is possible that lowering concentration of PDGF to 5 ng/ml was sufficient to induce
differentiation of primary OPCs by itself and that treatment was 10 μM compounds was
not sufficient to accelerate the differentiation process. Another possibility is that even 5
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ng/ml PDGF caused an inhibition of OPC differentiation that could not be overridden by
addition of 10 μM guanidine compounds.

Differentiation of Oli-neu cells along the oligodendrocyte lineage was assessed by
examining changes in endogenous transcription upon treatment with guanidine
compounds. Pdgfra transcript levels decreased upon treatment with guanidine
compounds. Unexpectedly however, Cnp transcription is inhibited as well. Although
some studies have implied that Olig2 gets downregulated in mature oligodendrocytes
(Ligon et al, 2006), ~15 fold decrease in Olig2 transcript level upon treatment with
guanidine compounds after only 2 days of treatment should not be attributed solely to
differentiation. Decrease in the transcript level of all oligodendrocyte-specific markers
observed upon treatment with Chembridge compounds might be explained by OPC fate
switch to astrocytes. However, this does not seem to be the case here since Gfap
transcript level is only marginally increased.

Taken together, our results suggest that although the transcript level of Pdgfra, one of
the

critical

factors

that

regulates

differentiation

of

OPCs,

gets

dramatically

downregulated upon treatment with guanidine compounds, this event is not sufficient for
differentiation to occur under given conditions. It is possible that guanidine compounds
target a specific receptor or pathway, but there are factors that need to be regulated at
the same time in order for successful differentiation to occur. This is supported by the
fact that there is a discrepancy between the effects observed when cells were treated
with Chembridge compounds compared to those when our own compounds were used.
Sample 40B10 contains traces of an unknown chemical, which might be responsible for
the inconsistent regulation of Ng2, Sox10 and Mbp transcripts. A combination of
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guanidine derivatives, which downregulate Pdgfra, with other compounds, that cause an
upregulation of Cnp and Mbp, might bring us closer to our goal.
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Chapter 5 - Determ ine w hether the com pounds inhibit OPC proliferation.	
  

Introduction

The roles of PDGF and PDGFRA in OPC proliferation and differentiation have been
extensively studied. Numerous studies have shown that PDGF is the major mitogen for
OPCs both in vitro and during development (Noble and Murray, 1984; Noble et al, 1988;
Richardson et al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff
et al, 1988; Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988; van Heyningen
et al, 2001). PDGF withdrawal from the culture medium or its block with anti-PDGF
antibodies is sufficient to induce OPCs to exit cell cycle and differentiate (Raff et al,
1985; Raff et al, 1988; Richardson et al, 1988; Noble et al, 1988). PDGF exerts its
effects though PDGFRA, which is the only PDGFR isoform expressed by these cells
(Pringle et al, 1992; Nishiyama et al, 1996; Dawson et al, 2003). PDGFRA disruption in
OPCs results in their premature differentiation in culture, whereas OPCs from PDGFRA
knockout mice show impaired proliferation (McKinnon et al, 2005). Since PDGFRA is
critical for OPC proliferation, we hypothesized that downregulating its transcription by
guanidine compounds would result in decrease in OPC proliferation.

We tested the effect of guanidine compounds on the proliferation of PDGFRAexpressing Oli-neu cells and primary mouse OPCs, as well as HEK 293 cells and
primary mouse astrocytes that do not express PDGFRA. We also examined the
proliferation of three glioblastima-derived cell lines that show different levels of PDGFRA
transcript (Lokker et al, 2002). Our results show that guanidine compounds robustly
inhibited proliferation of Oli-neu cells and primary mouse OPCs, while they did not alter
proliferation of HEK 293 cells and primary mouse astrocytes. Surprisingly, all
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glioblastoma-derived cell lines showed a very mild decrease in proliferation and their
response that did not correlate with the amount of PDGFRA transcript present. Contrary
to Oli-neu cells and OPCs, guanidine compounds did not downregulate PDGFRA
transcription in glioblastoma-derived cell lines.

Methods

Cell culture

Oli-neu cells were grown on poly-L-lysine-coated culture dishes. Cells were maintained
in growth medium consisting of DMEM/F12 (Gibco 11330) supplemented with 1% horse
serum (Hyclone SH30074.03), N2 supplement (Gibco 17502), 1X penicillin/streptomycin
(Gibco 15140). Glioblastoma-derived cell lines A172, U251 and T98G, as well as HEK
293 cells were grown in DMEM (Gibco 11960) supplemented with 10% FBS (Gibco
26140), 2 mM L-glutamine (Gibco 25030), 1X penicillin/streptomycin (Gibco 15140). All
cell cultures were maintained at 37°C in 5% CO2 in a humid atmosphere.

Mixed glial cultures were prepared as descried previously (Yang et al, 2005). Briefly,
cerebral cortices from P2-P4 FVB mice (Jackson Laboratory) were dissected out,
minced, triturated and plated in 25 cm2 culture flasks coated with 30 μg/ml poly-L-lysine
(Sigma). Cell cultures were maintained in DMEM (Gibco 11960) containing 10% FBS
(Gibco 26140) at 37°C in humidified air with 5% CO2. After 6-8 days, loosely attached
OPCs and microglia were shaken-off. Remaining astrocytes were trypsinized, collected
and plated on coverslips coated with 100 μg/ml poly-L-lysine at 5000 cells/coverslip.
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Primary mouse OPCs were obtained from P2 mouse cortices from FVB mice by
negative immunoselection using mouse anti-O1 and positive immunoselection using rat
anti-mouse PDGFRA (BD Pharmingen). PDGFRA positive cells were resuspended in
Sato’s medium supplemented with 50 ng/ml mouse PDGF (Peprotech), plated in poly-Llysine coated tissue culture dishes and allowed to proliferate for 3 days. Approximately
50% of medium was removed every day and replaced with 50% of fresh culture medium.
On the 3rd day, OPCs were trypsinized and resuspended in Sato’s medium that
contained 20 ng/ml mouse PDGF. They were plated in coverslips coated with 100 ug/ml
poly-L-lysine.

For proliferation experiments, cells were split to coverslips and treated with 50 μM
guanidine compounds for 2 days. EdU (Life Technologies C10337) was added to the
culture medium during the last 5h of incubation at the concentration of 10 μM. Cells were
then fixed with 4% PFA and immunostained. Click-iT EdU Alexa Fluor 488 Imaging Kit
(Life Technologies C10337) was used to label EdU+ cells.

Slice culture

Cortical organotypic slice cultures were prepared from P7-P8 NG2creBAC:ZEG double
transgenic mice (Zhu et al, 2008) as described previously (Bahr et al, 1995; Zhu et al,
2011; Hill et al, 2013). Briefly, 300 μm coronal forebrain slices were cut with a tissue
chopper and placed on Millicell culture inserts (Millipore PICM03050). Slices were
maintained at 37°C in 5% CO2 in a humid atmosphere. Slice medium contained 50%
Minimal Essential Medium with Earle’s Salts (MEM) (Gibco 11090), 25 mM HEPES
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(Sigma H-4034) buffer at pH 7.22, 25% Hank’s balanced salt solution (HBSS) (Gibco
14175), 25% horse serum (Hyclone SH30074.03), 0.4 mM ascorbic acid (Sigma A0278), 1 mM L-glutamine (Gibco 25030) and 1 μg/ml insulin (Sigma I-6634).

For proliferation experiments, slices were treated with 1 μM or 10 μM guanidine
compounds for 2 days in the medium that either had or did not have 50 ng/ml human
PDGFAA (R&D Systems 221-AA). EdU was added to the slice medium during the last
5h of incubation at the concentration of 10 μM. Slices were then fixed and EdU+ were
detected with Click-iT EdU Alexa Fluor 488 Imaging Kit (Life Technologies C10337).

Citotoxicity assay and flow cytometry

After 16h treatment with MMC or 50 μM guanidine compounds, Oli-neu cells were
harvested. Apoptotic cells were detected using Alexa Fluor 488 Annexin V/Dead Cell
Apoptosis Kit (Life Technologies V13241) according to manufacturer’s instructions with
one modification. After incubating cell suspension with Alexa Fluor 488 Annexin V and
propidium iodide, samples were washed once with 1 ml PBS in order to remove excess
dye. Immediately following staining 10,000 cells were counted and analyzed with flow
cytometry

(BD

FACSCalibur

flow

cytometer,

Biotechnology-Bioservices

Center,

University of Connecticut, Storrs). Analysis was done using FlowJo software.

To compare the effect of guanidine compounds on proliferation and toxicity, Oli-neu cells
were treated with 50 μM compounds for 16h with addition of EDU during the last 4h of
treatment. Then they were harvested, resuspended in PBS and fixed by addition of PFA
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to the final concentration of 2%. After washing once with PBS, pellets were resuspended
in 50 ul Click-iT reaction cocktail (Life Technologies C10337). After 30 min, suspension
was diluted to 500 ul with PBS. Cell pellets were collected, resuspended in 500 ul PBS
and analyzed with flow cytometry (BD FACSCalibur flow cytometer, BiotechnologyBioservices Center, University of Connecticut, Storrs). Analysis was done using FlowJo
software.

Results

Guanidine com pounds inhibit proliferation of Oli-neu cells

We previously demonstrated that 002, 005 and 008 caused a decrease in Pdgfra
transcript level, 002 having the most robust effect, whereas 006 and 012 did not alter
Pdgfra transcription (Chapter 5). Since PDGFRA gets downregulated with induction of
differentiation, decrease in Pdgfra transcription might correlate with decrease in Oli-neu
proliferation. In addition, we observed a striking difference in cell density when Oli-neu
cells were treated with guanidine compounds (Figure 12. A). We therefore wanted to
examine the possibility that the decrease in cell density is due to inhibition of
proliferation. For this purpose, we treated Oli-neu cells with guanidine derivatives 002,
005, 006, 008 and 012 for 2 days at 50 μM concentration and assayed the percentage of
proliferating cells during the last 5h of treatment (Figure 12. B and C). As expected,
compounds 002, 005 and 008 caused a dramatic decrease in proliferation, assayed by
the percentage of PDGFRA+/EDU+ among all PDGFRA+ cells. Surprisingly, although
006 did not inhibit Pdgfra transcription, treatment with 006 resulted in a significant
decrease in the percentage of proliferating cells. When cells were treated with 012, there
was a marginal decrease in proliferation that did not reach significance.
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Quantitative PCR was performed in order to assess transcript levels of cyclin-dependent
kinase inhibitors p21Cip1 (p21) p27Kip1 (p27), which were shown to be upregulated as
OPCs are exiting the cell cycle (Casaccia-Bonefil et al, 1997; Durand et al, 1997; Ghiani
et al, 1999). Our results showed that 002 caused the most robust increase in p21 and
p27 transcript levels, while 005 and 008 caused somewhat moderate increase.
Surprisingly, compound 006 resulted in less than 2-fold increase in transcript levels of
p21 and p27 (Figure 12. D and E). As expected, 012 did not an effect. Taken together,
these results suggest guanidine compounds inhibit proliferation of Oli-neu cells.

We also wanted to examine the potency of guanidine compounds with respect to their
effect on proliferation of Oli-neu cells. For this purpose, Oli-neu cells were treated with 5
guanidine derivatives at several concentrations for 2 days with addition of EDU during
the last 5h of treatment (Figure 12. F). Treatment with none of the compounds resulted
in a significant decrease in the percentage of PDGFRA+EDU+ cells at 1 µM. As
expected, compound 002 was the most potent, causing a robust decrease in the
percentage of PDGFRA+EDU+ cells at concentration as low as 10 µM. Although
treatment with 005 and 008 at 10 µM also inhibited proliferation and Oli-neu cells, this
effect was less robust. Contrary to that, 006 was effective only at 50 µM, while 012 did
not inhibit proliferation at any concentrations tested (Figure 12. F).

To determine whether decrease in cell proliferation is due to decreased expression of
PDGFRA in general or increased internalization of PDGFRA from the surface of Oli-neu
cells, we treated Oli-neu cells with guanidine compounds for 2 days at 50 µM and
performed live staining for PDGFRA (Figure 13. A). We quantified the percentage of Oli-
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neu cells that express PDGFRA on their surface at high level among all DAPI+ cells
(Figure 13. B). Cells that express PDGFRA at high level were distinguished from those
that express PDGFRA at low level by qualitative assessment of the intensity of
immunostaining. The amount of receptor present on the surface of these cells varied
within the cell population, even under control conditions. The percentage of cells
expressing PDGFRA at high level, among all PDGFRA+ cells followed the general trend
observed with proliferation experiments. However, the differences did not reach
significance under any conditions. These results suggest that upon 2-day treatment of
Oli-neu cells with guanidine compounds, majority of cells still express PDGFRA.
Therefore, change in receptor expression and/or internalization are not likely causing the
observed decrease in Oli-neu cell proliferation.

The decrease in cell density and proliferation of Oli-neu cells might be due to citotoxicity
of guanidine compounds. In order to test this, we cultured Oli-neu cells in the presence
of guanidine compounds for 16h. To detect cells that during this time underwent
early/intermediate stages of apoptosis, we performed Annexin V staining in combination
with propidium iodide (PI). Mitomycin C (MMC), an apoptotic inducer in variety of
cancers, was used as positive control. The percentage of Annexin V+ cells was
quantified by flow cytometry (Figure 14. A). Our results show that all guanidine
compounds, as well as MMC, caused an increase in the percentage of Annexin V+ cells
by at least 2 fold relative to control (Figure 14. B). We also examined proliferation of Olineu cells treated with guanidine compounds during the same time frame. The
percentage of EDU+ cells was quantified by flow cytometry (Figure 14. C). After 16h
treatment with compounds 005, 006 and 008, the percentage of EDU+ Oli-neu cells
decreased by approximately 2 fold relative to control. As expected, compound 002 was
the most potent, causing a decrease in the percentage of EDU+ cells close to 8 fold
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(Figure 14. D). Taken together, these results imply that guanidine compounds are at
least partially toxic. However, the effect of compound 002 cannot be attributed solely to
toxicity since the inhibition of proliferation is greater compared to toxicity.

Guanidine com pounds inhibit proliferation of dissociated prim ary m ouse
OPCs

The next question we asked was whether the inhibition of proliferation by guanidine
compounds is cell-type specific. Oli-neu cells were derived from primary mouse OPCs
by retroviral transduction with mutated analog of c-neu proto-oncogene. T-neu oncogene
differs from its analog by a point mutation, which causes t-neu to be constitutively active
and results in indefinite proliferation capacity of cells that carry this oncogene. Due to
different profile, OPCs might not necessarily respond in the same manner to guanidine
compounds.

We therefore wanted to examine whether change in OPC proliferation, as a response to
treatment with guanidine compounds, would occur in the manner similar to that of Olineu cells. To answer this question, dissociated primary mouse OPCs were treated with
002, 005, 006, 008 and 012 at 50 μM for 1 day. Compounds were added to the cells
together with 20 ng/ml mouse PDGFAA, a known survival factor and mitogen for OPCs,
which is necessary for maintenance of progenitor phenotype in dissociated cultures.
EDU was added during the last 5h of incubation when cells were fixed and stained for
PDGFRA (Figure 15. A). Our results indicate that, although the response of OPCs
followed a similar trend compared to that of Oli-neu cells, decrease in the percentage of
proliferating cells was less robust (Figure 15. B). As expected, 002, 005 and 008 were
the most potent, while 012 caused marginal decrease in the percentage of EDU+ cells.
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Treatment of OPCs with 006 resulted in a moderate decrease in proliferation that did not
reach significance.

OPCs are kept in dissociated culture in strictly defined medium and in an environment
that differs to that in vivo. To provide conditions more similar to those in vivo, we used
organotypic cortical cultures from NG2creBAC:ZEG double transgenic mice in which
EGFP is expressed in OPCs and their progeny. To examine proliferation of mouse
OPCs in slice cultures, we limited our treatments to compounds 002 and 006. These 2
compounds are positional isomers that differ only in the position of methoxy residue.
However, they exert different potency in terms of Pdgfra transcription and proliferation of
Oli-neu cells and OPCs. Cortices from NG2creBAC:ZEG mice were dissected and
incubated for 7-9 days. Compounds were added during the last 2 days of incubation
while EDU was added during the last 5h of treatment. Treatment with compound 002
resulted in a decrease in the percentage of EDU+ OPCs, which reached significance
only in white matter and only at the higher concentration applied. Although compound
006 also caused a decrease in the percentage of proliferating OPCs, this decrease was
not significant (Figure 15. C and D).

PDGF is the best known and most potent mitogen for OPCs. Addition of exogenous
PDGF was shown to increase proliferation of OPCs in white matter, but not gray matter
in organotypic slice cultures (Hill et al, 2013). We wanted to examine whether guanidine
compounds would block the effect of exogenous PDGF. For this purpose, we added
PDGF during the last 2 days of incubation to the final concentration of 50 ng/ml, as this
was the amount that has been shown to cause a plateau in OPC proliferation in slice
cultures. As expected, addition of PDGF resulted in an increase in proliferation in white
matter, but not gray matter (Hill et al, 2013). However, when PDGF was applied together
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with compounds 002 and 006, PDGF-induced proliferation was inhibited. Compound 002
was more potent and caused significant reduction in the percentage of EDU+ cells in
white matter even at low concentration of concentration of 1 µM, while treatment with
compound 006 resulted in inhibition of PDGF-induced proliferation only at higher
concentration of 10 µM. At 10 µM, compound 002 inhibited proliferation of gray matter
OPCs as well (Figure 15. C and D).

In our experiments with slice cultures, we also observed that OPCs were not the only
cells which proliferation was inhibited by guanidine compounds. Other cell types, which
we did not characterize, also incorporated EDU under control conditions and upon
addition of exogenous PDGF. EDU incorporation was dramatically reduced upon
treatment with guanidine compounds. This suggests that the effect our compounds exert
is not specific for oligodendrocyte-lineage cells.
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Figure 12. Changes in Oli-neu cell density and proliferation upon treatm ent
w ith guanidine com pounds. Oli-neu cells were treated with guanidine compounds for
2 days at 50 µM with addition of EDU during the last 5h of treatment. We observed a
striking difference in cell density (A). Oli-neu cells were fixed and stained for PDGFRA
(B). EDU+PDGFRA+ cells among all PDGFRA+ cells were quantified (C). Upon 2-day
treatment of Oli-neu cells with guanidine compounds, RNA was extracted. qPCR results
show an increase in the transcript levels of p21 and p27 (D and E). (F) Quantification of
PDGFRA+EDU+ among all PDGFRA+ Oli-neu cells after treatment with guanidine
compounds at different concentrations. * p < 0.05 relative to control, ** p < 0.01 relative
to control, *** p < 0.001 relative to control, one-way ANOVA with Bonferroni posthoc
analysis. Error bars are standard errors of the mean.	
  

95	
  

	
  

96	
  

Figure

13. Guanidine

com pounds

do not cause

decrease

in PDGFRA

expression or receptor internalization. Oli-neu cells were treated with guanidine
compounds for 2 days at 50 µM when live staining for PDGFRA was performed (A).
Quantification of the cells expressing PDGFRA at high level among all cells. Error bars
are standard deviations of the mean, no statistical significance was found, one-way
ANOVA with Bonferroni posthoc analysis.	
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Figure 14. Decrease in Oli-neu cells density upon treatm ent w ith guanidine
com pounds can be partially attributed to citotoxicity. Oli-neu cells were treated
with guanidine compounds for 16h when they were stained for Annexin V and PI.
Annexin V+ and PI+ cells were counted using flow cytometry (A). The percentage of
apoptotic cells, identified by Annexin V labeling, was quantified. All compounds caused
an increase in the percentage of apoptotic cells by at least 2 fold (B). We also examined
changes in proliferation in Oli-neu cells treated with guanidine compounds for 16h. Olineu cells that incorporated EDU were counted using flow cytometry. Histograms are
showing the number and percentage of EDU+ cells (C). Quantification (D) shows that
compounds 005, 006 and 008 caused approximately 2-fold decrease, while treatment
with 002 resulted in close to 8-fold decrease in the percentage of proliferating cells.	
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Figure 15. Changes in prim ary m ouse OPC proliferation after treatm ent w ith
guanidine com pounds. After 1-day treatment of primary mouse OPCs with guanidine
derivatives at 50 μM, OPCs were stained for PDGFRA and EDU (A). (B) Quantification
of the PDGFRA+ cells that incorporated EDU during the last 5h of treatment among all
PDGFRA+ cells. Compounds 002, 005 and 008 caused a significant decrease in the
percentage of proliferating cells, 002 being the most potent. * p < 0.01 relative to control,
** p < 0.001 relative to control, one-way ANOVA with Bonferroni post-hoc analysis. Error
bars are standard errors of the mean. (C) Organotypic cortical slice cultures obtained
from NG2creBAC:ZEG double transgenic mice were exposed to guanidine compounds
for 2 days with and without addition of exogenous PDGF. EDU was added during the
last 5h of treatment when slices were fixed and stained for EDU (red). (D) Quantification
of the GFP+ cells that incorporated EDU during the last 5h of treatment among all GFP+
cells. + p < 0.001 relative to gray matter, # p < 0.001 relative to respective control, * p <
0.001, two-way ANOVA with Bonferroni post-hoc analysis.	
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Guanidine com pounds do not inhibit proliferation of glioblastom a-derived cell
lines, prim ary astrocytes and HEK cells 	
  

To further address the question whether compounds-induced inhibition of proliferation is
specific for PDGFRA-expressing cells, we tested the effects of guanidine compounds on
several other cell types. All treatments were done as previously. Cells were treated with
50 μM compounds for 2 days with the addition of EDU during the last 5h of treatment.
Then, they were fixed and stained for EDU and the percentage of EDU+ cells among all
cells, identified by DAPI, was quantified.

Astrocytes and HEK 293 cells do not express PDGFRA. Therefore, we hypothesized
that guanidine compounds would not inhibit proliferation of these two cell types. As
expected, treatment with none of the compounds resulted in a decrease in the
percentage of EDU+ cells (Figure 16. A).

Glioblastoma-derived cell lines A172, U251 and T98G differ in transcript levels of
PDGFRA and PDGFRB. Compared to the remaining two cell lines, U251 has the highest
level of PDGFRA, while A172 has the highest level of PDGFRB transcript. T98G has
moderate levels of both PDGFRA and PDGFRB. Therefore, U251 most closely
resembles OPCs (Lokker et al, 2002). We hypothesized that, upon treatment with
guanidine compounds, U251 would show the most robust decrease in the percentage of
EDU+ cells, T98G would show modest decrease, while A172 would have little or no
response. Quantification of the percentage of EDU+ cells showed that all 3 glioblastomaderived cell lines respond in a manner that resembles that of Oli-neu cells. However,
contrary to that of Oli-neu cells, the observed decrease in proliferation was modest for all
cell lines. None of the compounds significantly reduced proliferation of U251 and T98G.
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Unexpectedly, compounds 002 and 005 caused a significant decrease in the
proliferation of A172. However, the decrease in proliferation was less robust compared
to the one observed with Oli-neu cells or primary mouse OPCs (Figure 16. B). We also
wanted to examine whether guanidine compounds would alter PDGFRA transcription in
glioblastoma-derived cell lines. Our qPCR results showed that the change in PDGFRA
or PDGFRB transcript levels upon treatment with guanidine compounds was marginal
and it did not reach 2 fold (Figure 16. C).
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Figure 16. Guanidine com pounds inhibit proliferation of A172, but do not inhibit
proliferation of U251, T98G, HEK 293 cells and prim ary m ouse astrocytes. Cells
were treated with guanidine compounds for 2 days when the percentage of EDU+ cells
among all cells was assessed. Bar graphs show quantification of cells that incorporated
EDU during the last 5h of treatment. Primary mouse astrocytes and HEK 293 cells did
not show a change in proliferation (A). The three glioblastoma-derived cell lines showed
proliferation changes similar to those of Oli-neu cells and OPCs. However, the decrease
in proliferation was not significant in any circumstances, except when cell line A172 was
treated with compounds 002 and 005 (B). * p < 0.05 compared to control, ** p < 0.01
compared to control, one way ANOVA with Bonferroni post hoc analysis. (C) We
analyzed the changes in Pdgfra and Pdgfrb transcript levels after glioblastoma-derived
cell lines had been treated with guanidine compounds for 2 days. Changes in
transcription in all three cell lines were marginal and less than 2-fold under all conditions
examined. dCtC = delta Ct of DMSO control; dCtT = delta Ct upon treatment with
compounds.	
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Discussion 	
  

Since signaling through PDGFRA is critical for OPC proliferation, we hypothesized that
downregulation of Pdgfra transcription would inhibit proliferation of PDGFRA-expressing
cells. As expected, the percentage of proliferating Oli-neu cells and primary mouse
OPCs was robustly reduced upon treatment with guanidine compounds. Decrease in cell
proliferation might be due to toxicity since treatment with guanidine compounds resulted
in an increase in the percentage of apoptotic Oli-neu cells by approximately 2 fold. This
might be the case for compounds 005 and 008 where decrease in proliferation under the
same conditions was also 2 fold. However, decrease in proliferation cannot be attributed
solely to toxicity for compound 002. Although 16h treatment with 002 resulted in 2.1-fold
increase in the percentage of apoptotic cells, decrease in proliferation observed under
the same conditions was 7.7 fold.

Decrease in OPC proliferation is also evident in organotypic slice cultures. Only high
dose of more potent compound 002 was able to inhibit proliferation under basal
conditions. However, when compounds were added together with PDGF, they inhibited
PDGF-induced proliferation of OPCs. Low dose of compound 002 and high dose of
compound 006 were required for this effect. Upon 2-day treatment of Oli-neu cells,
PDGFRA protein was shown to be present on the cell surface. We did not examine the
expression of PDGFRA on the surface of OPCs in the slice culture. However, since slice
cultures were treated with compounds for 2 days, it is possible that primary OPCs
showed continues expression of PDGFRA at this time as well. This suggests that
PDGFRA is not the primary target for guandince compounds. This is further supported
by our observation that proliferation of GFP- cells, which are unlikely of oligodendrocyte
lineage, was also inhibited by guanidine compounds.
106	
  

Both Oli-neu cells and OPCs express PDGFRA, while HEK 293 cells and astrocytes do
not, so it is possible that PDGFRA downregulation is at least in part responsible for the
observed decrease in proliferation. This appears to contradict the result obtained from a
similar experiment that utilized glioblastoma-derived cell lines. However, we need to
keep in mind that glioblastoma-derived cell lines used in our study might not necessarily
be derived from oligodendrocyte lineage cells. It is possible that they express other
growth factor receptors and that signaling through these pathways overrides the effect of
compounds. Another possibility is that target molecule for compounds that regulates
Pdgfra transcription is not expressed by glioblastoma-derived cell lines. This is
supported by the fact that treatment with guanidine compounds did not result in a
decrease in PDGFRA mRNA level in glioblastoma-derived cell lines.
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Chapter 6 – Sum m ary, discussion and conclusions 	
  

Sum m ary

OPCs are the major source of oligodendrocytes during embryonic development and
adulthood, but also in pathological conditions. Since OPCs are the largest pool of cycling
cells that are readily available for recruitment upon myelin injury, they represent an
attractive target for therapies for demyelinating disorders. Signaling through PDGFRA is
the key mechanism that regulates OPC proliferation and their differentiation into mature
oligodendrocytes. Aberrant PDGFRA expression has been implied in the occurrence of
CNS malignancies and inhibition of PDGFRA signaling could be a valuable addition to
the current treatments of certain CNS cancers. Small molecules are putative candidates
for the therapeutic interventions because they can be designed to be highly specific for
their targets to be able to cross blood brain barrier. Identification of such compounds
might provide a novel direction in the drug design for nervous system disorders. Since
PDGFRA is critical for regulation of OPC proliferation and differentiation, identification of
compounds that target regulators of its expression and/or signaling could provide a
significant contribution to treatments of demyelinating disorders and CNS malignancies.

The purpose of this study was to identify small molecule compounds that downregulate
Pdgfra transcription in OPCs. We hypothesized that the inhibition of transcription of this
particular receptor would result in inhibition of OPC proliferation and stimulation of their
differentiation into mature oligodendrocytes.

In the primary screen, we indeed identified 7 compounds that downregulated PDGFRAluc activity in a dose-response manner. Guanidine compounds (39D11, 40A10, 40B10
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and 39E11) also downregulated endogenous Pdgfra transcription, assessed by qPCR,
while structurally non-related compound 42E8 did not. Downregulation of transcription
was specific for Pdgfra and not for other RTKs expressed by OPCs. Guanidine
compounds also inhibited proliferation of Oli-neu cells and primary mouse OPCs,
assessed by EDU labeling, but did not inhibit proliferation of primary mouse astrocytes,
HEK 293 cells and glioblastoma-derived cell lines. They did not, however, promote
differentiation of primary rat OPCs into mature oligodendrocytes.

Discussion

Luciferase assay is a powerful tool widely used for high-throughput screening purposes.
However, studies using luciferase assay are most commonly done on stably transfected
cell lines where firefly luciferase is driven by gene’s endogenous regulatory sequences.
Using only a portion of Pdgfra gene to drive reporter expression was a disadvantage in
our primary screen, which could be overridden by stable transfection of Oli-neu cells.

To identify compounds that promote differentiation, a valuable addition to the technique
would be to use a second plasmid for the primary screen, which contains regulatory
elements of an early oligodendrocyte gene driving reporter transcription. Cnp would be a
good choice for this purpose, since it gets upregulated when Oli-neu cells are treated
with differentiation inducers (Joubert et al, 2010). Differential regulation of OPC-specific
and early oligodnedrocyte gene in differentiating Oli-neu cells would prevent selection of
false positives.
Oli-neu cells are immortalized cell line and, in our hands, they were less responsive to
differentiation inducers than primary OPCs. At the time when screening was preformed,
we could not obtain sufficient numbers of viable OPCs and therefore chose to use Oli109	
  

neu cells instead. Using primary OPCs from one of the numerous transgenic mouse
lines available that have florescent reporter driven by regulatory sequences of OPC- and
oligodendrocyte-specific genes might provide better biological system to detect
differentiating OPCs.

SAR analysis of guanidine compounds revealed residues that are responsible for
compounds’	
   potency. Two structural modifications that resulted in the highest potency of
guanidine compounds are: presence of methoxy group at carbon 2 of the benzyl ring
and elongation of the carbon chain linking guanidine group and benzyl ring. Such
modifications might exert their effect by increasing compound lipophylicity, stabilizing
compound-target interaction or facilitating the interaction between the pharmacophore
and the receptor. A combination of these and other modifications might further improve
compound potency (Figure 9). Once the top candidates are ready to be tested for their
biological effect in vivo, replacement of hydrogen atoms with fluorine might be a valuable
modification. Presence of fluorine may extend compound’s half-life without affecting the
biological activity if such replacement is done at the site of metabolic oxidation.

We did not perform thorough analysis of a relationship between compound structure and
toxicity. Although our top candidate’s biological effect greatly surpasses its toxicity,
guanidine compounds were found to be at least partially cytotoxic for Oli-neu cells
(Figure 14). Further analysis needs to be conducted to identify residues that are
responsible for compounds’	
   toxicity and which structural modifications can be made to
decrease it.
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Guanidine compounds dramatically inhibited Pdgfra transcription and proliferation of Olineu cells. They did not, however, promote their differentiation into oligodendrocytes.
Together with the data obtained from experiments performed on primary OPCs, these
results suggest that downregulation of Pdgfra transcription and inhibition of proliferation
is not sufficient for OPC differentiation to occur under the conditions we used. This is
consistent with studies that suggest cell cycle withdrawal is necessary, but not sufficient
to induce OPC maturation and that control of oligodendrocyte differentiation involves
other factors that operate between cell cycle exit and differentiation (Casaccia-Bonefil et
al, 1999). Identification of compounds that target such factors will contribute in
succeeding in our goal to use small molecule compounds as additional therapy for
demyelinating disorders.

Together with the correlation between downregulation of Pdgfra transcription and
inhibition of Oli-neu cell proliferation, lack of compounds’	
   effect on astrocytes and HEK
293 cells, which do not express PDGFRA, implies that Pdgfra is a direct/indirect target of
guanidine compounds. This is further supported by the fact that neither PDGFRA
transcription nor proliferation of two glioblastoma-derived cell lines was inhibited by
guanidine compounds. However, since compounds 002 and 005 inhibited proliferation of
A172 but did not downregulate transcription of PDGFRA or PDGFRB in these cells, this
leads to speculation that PDGF receptors are not the only targets for guanidine
compounds. This is consistent with the biological effect of compound 006, which did not
alter Pdgfra transcription, but did inhibit proliferation of Oli-neu cells. Future research,
aimed toward identifying direct target/s of guanidine compounds, will contribute to the
growing knowledge of PDGFRA regulation and its role in OPC differentiation.
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It was encouraging to discover that the effect of guanidine compounds is somewhat celltype specific, since proliferation of Oli-neu cells and primary OPCs was inhibited by
guanidine compounds, but that of astrocytes and HEK 293 cells was not. However, we
also observed a decrease in the percentage of EDU+ cells that were not GFP+ in our
slice culture system, which implies guanidine compounds act on a broader spectrum of
cell types. Although proliferation of glioblastoma-derived cell lines was not efficiently
inhibited, this does not necessarily mean that cells derived from other types of cancers
would respond similarly to the three cell lines examined. It would be interesting to find
out whether cells obtained from biopsies of patients with gliomas would be more
responsive. In addition, characterization of cell types that these compounds are specific
for might provide us with a direction toward other types of cancers that can be potentially
treatable.

To this date, the effect that N-methyl-N-benzyl guanidine or its derivatives have on
proliferation of varios cell types has never been examined. In fact, to my best
knowledge, none of the guanidine compounds identified in this study, have been
examined in other types of bioassays. However, several other guanidine derviatvies
have been tested in 2 other studies. These compounds were not, however, derivatives of
our lead compound, N-methyl-N-benzyl guanidine, but of another lead, N-benzyl
guanidine, which does not have methyl group on the nitrogen athom of the guanidine.
Four compounds were candidates in the high throughput screening study related to
obesity and diabetes, aimed towards identifying small molecule compounds that would
alieveiate these disorders. These compounds were: N-(2-chloro-benzyl)guanidine, N-(2methoxy-benzyl)guanidine,

N-(3-methoxy-benzyl)guanidine

and

N-(4-methoxy-

benzyl)guanidine. They were identified as top candidates from the screening. However,
eventually, they were shown to be inactive. In a separate study, aimed towards
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identifying inhibitors for substrates of cytochrome p450 in a high throughput screen, a
different derivative of N-benzyl guanidine, N-(3-iodo-benzyl)guanidine, was identified
and shown to be active. This compound has iodine as a substituent on the benzyl ring.
Results of these studies are encouraging as they support our conclusions that presence
of chlorine and methoxy groub on C2 and C3 of the benzyl ring might be an important
modification. In addition, we should also consider using iodine as substituent as well.

	
  
Aberrant PDGF and PDGFR expression has been detected in various types of
malignancies, including those occurring in the CNS (Hermanson et al, 1992; Di Rocco et
al, 1998; Martinho et al, 2009; Ozawa et al, 2010; Heldin, 2013). PDGFRA is the second
most frequently mutated RTK gene in glioblastoma (The Cancer Genome Atlas
Research Network, 2008). Amplification is the most commonly observed PDGFRA gene
alteration, while point mutations, deletions and gene rearrangements are rare and occur
more frequently in glioma samples that already have PDGFRA amplification (Martinho et
al, 2009; Verhaak et al, 2010; Ozawa et al, 2010).

Awareness of the PDGF signaling contribution to cancer growth has led to development
of different types of inhibitors that are now under preclinical and clinical evaluation
(Pietras et al, 2003; Heldin, 2013). Antibodies and soluble extracellular parts of the
receptors can intervene with PDGF signaling by binding to PDGFs or PDGFRs, prevent
their interaction or promote their degradation (Hawthorne et al, 2008; Shen et al, 2009).
Although reasonably specific, these types of inhibitors are expensive and difficult to
administer. Using small molecule compounds for cancer therapy has numerous
advantages –	
   they are potent, less expensive and easier to administer. Numerous
studies have explored the effects of developing compounds and several compounds
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were shown to be very promising in cancer treatment. However, none of these
compounds is specific and they were all shown to inhibit other kinases (Morris and
Abrey, 2010; Paulsson et al, 2011; Heldin, 2013). Imatinib is one of the first and most
promising candidates used in the treatment of multiple cancers, such as chronic
myelogenous leukemia and gastrointestinal stromal tumors (Iqbal and Iqbal, 2014).
However, in addition to PDGFRA, imatinib inhibits two other RTKs, Abl and Kit, as well
as serine/threonine kinase Raf (Heldin, 2013). The lack of specificity of imatinib and
other small molecule compounds contributes to their side effects. In addition, imatinib
was shown to have mild potency in clinical trials in glioma patients (Reymond et al,
2008), which might be attributable to its poor penetration through the blood brain barrier
(Takayama et al, 2002; Senior, 2003).

In addition to the lack of imatinib’s specificity, its action, as well as that of other
compounds, is directed towards inhibiting PDGFRA kinase activity and has not been
successful in treatments of gliomas. Targeting PDGFRA activity in its core, through
regulation of its transcription, might prove to be more effective. Guanidine compounds
discovered in our study were shown to be specific for Pdgfra transcription and not that of
other tested RTKs, Fgfr1 and Fgfr3, and therefore represent promising candidates for
future cancer therapies. In addition, their lower molecular weight might contribute to
easier delivery to the CNS. Future research needs to be conducted to assess guanidine
compounds’	
  transportation and metabolism.
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Concluding rem arks
Glial cell dysfunctions are involved in the occurrence and development of many nervous
system disorders. The dynamic of the disease progress is such that it often prevents the
development of the diagnostic and therapeutic strategies applicable at each time point
and in every location. One of the most important initiatives in the therapy today is
development of treatments that are personalized and tailored to the biology and stage of
the disease in the individual patients. Small molecules are putative candidates for
therapeutic interventions in the brain because they can be designed to be highly
selective, are able to cross blood brain barrier and can be conveniently modified to
adjust to different conditions, such as different patients or pathological processes.
Identification of such molecules may provide a novel direction in the drug design for
devastating nervous system disorders, which can complement current treatments.
PDGFRA signaling pathway is an attractive target for small molecules. Pdgfra
transcription and proliferation of PDGFRA-expressing cells were found to be inhibited by
compounds discovered in our study. How specific these compounds are and whether
they can be used to inhibit PDGFRA signaling in vivo remains to be established.
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